PHARMACEUTICAL INDUSTRY

Strategy & Research Department (2023).

CONTENTS

Executive Summary

Value Chain	• Suppliers (local and overseas). • Manufacturers. • Importers of finished products • Distributors. • Retailers • Consumers.
Key Players	• Danadams Pharmaceuticals • LeGray Chemicals • M & G Pharmaceuticals • Kama Industries • Ernest Chemist. • Amposah Efah Pharmaceuticals
Demand dynamics	• The demand for pharmaceutical products in Ghana has been influenced by economic factors such as incomes and increasing populations and specific government policies. The four (4) main factors that drive the purchase of a particular drug in relation to direct consumers are: o Affordability: people usually want to pay for drugs that are not expensive. o Effectiveness: consumers would always want to buy a drug that really works. o How well known the brand is: majority of people are scared to use a drug they haven't heard so much about. o Doctor's prescription
Supply/Distribution dynamics	• Pharmaceutical products are either manufactured locally or imported into the country. In some cases, just the raw materials are imported but the finished products are made here in Ghana. The hub of the pharmaceutical wholesale market is the Accra suburb of Okashie, though other major towns like Kumasi and the twin-city of Sekondi and Takoradi have relatively smaller hubs of wholesalers. There are 30 registered pharmaceutical manufacturers in Ghana and these companies serve the hundreds of pharmaceutical wholesalers directly. Some of the pharmaceutical producers have their own wholesale stores in Accra and other cities. Pharmaceutical wholesalers supply products to both the public and private sectors.
Regulatory Dynamics	• The pharmaceutical regulatory environment in Ghana is governed by the Food and Drugs Authority (FDA). The Ghanaian FDA has its own drug-testing facilities which test medicines as part of its post-marketing surveillance strategy.
Trade dynamics	• As with most emerging African countries, Ghana has a negative trade balance in relation to pharmaceutical trade. According to the Ghanaian health service, only 30% of the national requirements of pharmaceutical products are produced in Ghana, while the remaining 70% are imported. However, the Ghanaian government has emphasized the need to manufacture more locally produced medicines over the next decade, an ambition it shares with many African governments.
Foreign Exchange dynamics	• Availability of forex is key to this sector because 70% of pharmaceutical products are imported into the country. The players in this sector source for foreign exchange for the importation of the needed raw materials and finished products through their local bank. As the sector generates most of its revenues in Cedis, fluctuations in exchange rate affects cost of sales. The key players because of exposure to volatility in local currency to foreign currencies especially the dollar use derivative hedging strategies and engage also in forward contracts to minimize the effect of currency fluctuations. The sector requires over $250 million in FX annually.
Risk Consideration	• The high cost of borrowing. • Lack of access to investment or developmental capital. • Inadequate human resource availability. • Importation of cheaper sub-standard drugs. • Counterfeiting.
Key Success Factors	• Research and Development. • Disease burden. • Brand/product visibility. • Innovation. • Wide and effective distribution network. • Cost effective production process.
Banking Needs	• Short-term financing • Trade finance • Suppliers' Finance • Long term finance • Consumer loans • Payroll management • Working Capital finance

1.0 Background

Generally, the pharmaceutical industry is comprised of companies engaged in researching, developing, manufacturing and distributing drugs for human or veterinary use. New drugs have an enormous positive influence on global health, prosperity and economic productivity by saving lives, increasing life spans, reducing suffering, preventing surgeries and shortening hospital stays. Pharmaceuticals (biopharmaceuticals, drugs, medicines) are defined as any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or any substance (other than food) intended to affect the structure or function of the body.

The pharmaceutical sector in Ghana mainly comprises of producers of drugs, wholesalers, distributors, retailers and consumers. Ghana's pharmaceutical market is among the largest in the West African region, yet remains small on a global scale because its attractiveness to innovate drugmakers remains limited with underlying industry-associated risks. Ghana's pharmaceutical market was valued at GHS 6.8 billion ($826 million) in 2022, that is, 52.39% year-on-year growth which is relatively moderate in global terms and even by regional standards. This is projected to reach GHS7.7 billion ($634mn) by 2023. Prescription medicines dominate the market representing 74% by market value, while over-the-counter (OTC) medicines occupy a considerably smaller share at 26%. The prescription market share is split between patented drugs and generic drugs. However, we expect the market to become increasingly penetrated by generic medicines over the long-term, somewhat eroding patented medicines' share. Pharmaceutical sales accounted for 0.60% of GDP and 18.2% of total healthcare expenditure in 2021.

As of 2021, healthcare expenditure in Ghana was valued at GHS14.5bn (USD2.4bn), with public healthcare expenditure accounting for just over 45% of the overall market share. We expect this to increase as a proportion of total healthcare spending as demand for healthcare increases and gradual reforms to Ghana's National Health Insurance Scheme (NHIS) are implemented. Healthcare spending represents 3.5% of GDP with per capita spending at USD81.2. Private healthcare expenditure was valued at GHS8.4bn (USD1.4bn) in 2021, corresponding to 55% of the total market share.

Within this market, the government of Ghana is a major player, both as a regulator of the market and as a buyer involved directly in the wholesale and supply of drugs and healthcare services. Concerns about the provision of relatively cheap and effective drugs to the mass population have led to several government-led and/or private sector-led initiatives in the pharmaceutical sector of Ghana.

In April 2023, Ghana became the first country to approve the University of Oxford’s malaria vaccine, marking a major win for the programme after decades of research. The shot known as the R21/matrix-M malaria vaccine is the first malaria vaccine to meet the WHO’s 75% target for malaria vaccine efficacy. Grounds was broken on the manufacturing facility of DEKs Vaccines, a private sector-led consortium of local pharma firms. The plant is expected to manufacture about 600mn vaccines annually for malaria, pneumonia, rotavirus and cholera with a full value chain.

The Pharmaceutical Manufacturers Association of Ghana has 35 registered members, with domestic companies accounting for 30% of the country's pharmaceutical market. The main domestic players are Danadams, M&G Pharmaceuticals, Ayrton Drug Manufacturing, LaGray Chemical Company, Tobinco Pharmaceutical, Natural Scientific Pharmaceuticals, Aidcom, Alhaji Yakubu Herbal Company, Cima Pharmaceutical, Goldleaf Pharmacare, Health Concept Pharmaceutical and King David Pharmaceuticals. There is a multinational presence in Ghana, and some work in collaboration with local firms through domestic partnerships - GlaxoSmithKline, for example, uses Ghanaian firm Ernest Chemists (which works in retail, distribution and drug manufacturing).

Against this background, this report analyses the pharmaceutical industry in Ghana indicating the major player, how their products are distributed, regulations, key risk consideration, success factors of the industry and backing needs for resource allocation by GCB.

1.1 Supply Chain

Figure 1: Pharmaceutical Supply Chain



1.2 SWOT Analyses

The table below provides the SWOT analyses of the Pharmaceutical industry in Ghana.

Table 1: SWOT Analyses

Strengths	Weaknesses
• One of the most attractive pharmaceutical markets in West Africa. • A local manufacturing sector that benefits from government support. • The National Health Insurance Scheme, which provides basic care to the majority of the population.	• Low incomes and limited out-of-pocket spending power. • Pharmaceutical market that is dominated by sometimes high-priced branded generics from India. • Highly dependent on pharmaceutical imports.

• The government's package of investment into the country's healthcare sector. • The launch of the revised National Health Policy to prove a clear policy direction to the government in the provision of improved healthcare over the next ten years	
Opportunities	**Threats**
• Domestic drug makers are moving towards achieving WHO qualification and GMP certification, supported by the government's policies. • Ghana's evolving demographic and epidemiological profile will provide increased revenue earning opportunities for pharmaceutical companies, particularly those producing non-communicable disease treatments. • Local drug makers are in a favourable position for entering joint ventures with foreign pharmaceutical firms, particularly as regional exports are becoming more important. • Partnerships between foreign multinationals and the local government, which aim to upgrade existing infrastructure. • Government funding to promote the country's pharmaceutical sector under its Coronavirus Alleviation. • Programme, and industry support to promote the domestic pharmaceutical manufacturing industry.	• Financial sustainability will continue to limit the success of Ghana's National Health Insurance Scheme. • Counterfeit drugs, mainly from abroad, threaten to undermine sales from genuine pharmaceuticals. • Generic competition from more established manufacturing bases - such as India - will continue to pose threats to domestic manufacturing. • Prolonged disruption of the global pharmaceutical supply chain could lead to temporary drug shortages.

Source: Fitch Solutions

1.3 Competitive Landscape

The competitive environment in Ghana's pharmaceutical market will continue to be dominated by local firms and Indian companies. As of July 2022, according to Ghana's Food and Drug Authority, there were thirty-two (32) registered local manufacturing facilities with valid licenses, five (5) with expired licenses with no cancelled or revoked licenses. Majority were from India (See Annex 1 for list of Companies). On 15/1/2020 Dannex, Ayrton and Starwin merged to be known as DASPHARMA. Similarly we have fifty-nine (59) Foreign Pharmaceutical manufacturing companies with valid licenses, Ninety (90) with expired licenses and none has either been cancelled or revoked.

On the other hand as of January 2023, the Pharmaceutical Manufacturers Association of Ghana had 36 registered members. Most of the major local pharmaceutical companies also export their products to other countries in West Africa. Domestic drugmakers predominantly produce generic malarial, antiretroviral and OTC medicines, such as analgesics. The main domestic players are Danadams, M&G Pharmaceuticals, DASPHARMA, LaGray Chemical Company, Tobinco Pharmaceutical, Natural Scientific Pharmaceuticals, Aidcom, Alhaji Yakubu Herbal Company, Cima Pharmaceutical, Goldleaf Pharmacare, Health Concept Pharmaceutical and King David Pharmaceuticals.

Some of the key stakeholders in the Pharmaceutical Industry include:

- **Local Manufacturers**: Producers of finished pharmaceutical goods from raw materials (especially on a large industrial scale) within Ghana. Domestic producers in Ghana chiefly manufacture generic drugs. Although multinational drug makers operate in Ghana, we believe the market is increasingly shifting in favour of generic medicines, thus favouring domestic production. Foreign generic drugmakers in India and China have a growing influence. Over the long term, as the domestic industry grows, we expect generic drug makers to increase production in order to meet rising demand and cost-containment measures encouraged by the Ghanaian government.

- **Importers of Pharmaceutical Products**: Importers for customs purposes – the party who makes (or on whose behalf an agent or broker makes) the import declaration, and who is liable for the payment of duties (if any) on the imported pharmaceutical goods. Normally, this party is named either as the consignee on shipping documents and/or as the buyer on the exporter's invoice. Indian and European pharmaceutical companies will continue to dominate the pharmaceutical import market of Ghana. The table below illustrates the main multinational drug maker activity in Ghana. Some firms have formed partnerships with local drug makers, supported investment towards local research or implemented training and awareness programmes. Given the highly rural nature of the Ghanaian population, and its general lack of healthcare coverage, the ongoing efforts between foreign drug makers and the Ghanaian public healthcare sector are important steps in order to boost the commercial viability of medicine programmes.

MULTINATIONAL MARKET ACTIVITY

Company	Operations
Novartis	Novartis and its generic subsidiary Sandoz have offices in Accra. The Novartis Foundation has a community-based project in Ghana to improve healthcare access with more readily available treatments. 'ComHIP' has been designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana. Besides malaria awareness programmes, the Novartis Foundation is involved in telemedicine trials in remote communities of Ghana. The Ghana Health Service and MoH set up and staffed six teleconsultation centres in 2018 and Novartis said full national coverage was expected to be possible by 2019. Novartis is aiming to increase its presence within Ghana through sales from cardiovascular-related products, for example by investing heavily into single-tablet combination drugs for hypertension, as part of its diverse portfolio. In January 2019, the MoH signed a Memorandum of Understanding with Novartis, a new public-private partnership aimed to improve diagnosis and accelerate treatment for people with Sickle Cell Disease in the country.

Johnson & Johnson	Johnson & Johnson is present in Ghana through its subsidiary Janssen Pharmaceuticals. Its products are imported and it primarily uses the local representative Abba Scientific Promotion as well as Ernest Chemicals. Johnson & Johnson works through locally appointed partners for the distribution of products in disease areas including gastrointestinal disorders, antifungal treatments, schizophrenia and anaemia associated with chronic renal failure. In 2017, Johnson & Johnson announced its plans to position Ghana as its regional pharmaceutical hub for West Africa. The company also plans to launch public health units in Ghana and Kenya over the coming years. In 2018, Johnson & Johnson participated in awareness campaigns covering Mental Health and Prostate Cancer in Ghana. In 2020, the company launched a major support programme for prostate cancer patients in Ghana who are on or are to commence treatment to be able to afford the treatment, access their medication in the most convenient way, be aided to keep up doctor appointments, share their concerns regarding the disease and its management and be guided through all the various stages in the disease pathway. Janssen implementation partner, IQVIA will provide education on the disease and be responsible for taking the patient through the journey.
Pfizer	Pfizer is represented in Ghana through its regional office, with products being imported. In 2017, Pfizer rolled out a training programme for GPs in Ghana, Kenya and Nigeria using technology to strengthen the link between patients and healthcare providers. In 2021, the Pfizer Foundation donated USD6.4mn in grants to address critical infectious disease challenges in Nigeria and Ghana. The donation forms part of the organisation's long-term commitment to help protect underserved people in the United States of America, and around the world and will support programmes to reduce childhood mortality, improve maternal health and address the growing threat of antimicrobial resistance (AMR) in the two countries.
Roche	Roche's representative office is located in Accra. The Ghana Medical Association collaborated with Roche on a five-year cancer care project across the country (2015-2020). All healthcare practitioners are being trained on early detection and timely referral of suspicious cases to specialists in a bid to improve cancer care in the country. Roche regularly carries out cancer screening and awareness campaigns in Ghana, particularly following the agreed Memorandum of Understanding with the MoH. In January 2019, Roche Ghana, in collaboration with the MoH and the Ghana Health Service, launched the first National Guideline for Cancer Management. In 2022, Roche announced a new partnership with the government of Ghana to expand access to oncology services for the Ghanaian people, beginning with the opening of a new cancer treatment centre at the Cape Coast Teaching Hospital. Through the partnership agreement, Roche will work with the Ministry of Health to develop infrastructure by launching oncology services in three new cancer treatment centres,

Company	Operations
	supporting capacity development, and training for health care providers and supporting awareness creation in communities..
Sanofi	Sanofi's products are imported into Ghana. The company uses local representatives Gokals-Laborex and Reiss & Co. Sanofi Ghana has launched Aprovasc (irbesartan/amlodipine), a fixed-dose combination treatment for the management of hypertension. In 2021, IDF and Sanofi-Aventis Nigeria Ltd, a subsidiary of the Sanofi group, entered a partnership to help fight the rising burden of diabetes in Nigeria and Ghana. The IDF-Sanofi partnership will provide healthcare professionals in Nigeria and Ghana with training in diabetes care through the IDF School of Diabetes online educational platform. A total of 850 primary care physicians, general practitioners, nurses and pharmacists will be trained over a period of two years
Merck & Co	Merck & Co opened its first Ghanaian office in Accra in 2014. According to the firm's representatives, this decision makes up part of Merck & Co's strategic expansion in the ECOWAS sub-region, utilising Ghana as its operational hub given its relatively stable and transparent business environment. Merck's products are imported and handled by local representatives including Ernest Chemicals, Gokals-Laborex, Prime Health Services and Reiss & Co. In 2020, Ghana became one of the five African countries to license Merck's highly effective Ebola vaccine, rVSV-ZEBOV-GP. This meant that the vaccine could be administered in those countries without being subject to clinical trial or research protocols after it was pre-qualified by WHO that it met quality, safety, and efficiency standards.
GlaxoSmithKline	GlaxoSmithKline does not manufacture locally but does have a representative office in Ghana. GlaxoSmithKline also works in collaboration with Ernest Chemicals and some products manufactured in Nigeria are exported to Ghana. In 2017, GlaxoSmithKline terminated its distributorship contracts for its pharmaceuticals to four local Ghanaian companies, namely Ernest Chemists, Unicom Chemists, Gokals Laborex and Parkenstein. GlaxoSmithKline now operates solely through Worldwide Health, a wholly-owned Indian company operating in Ghana.

- **Wholesalers**: Firms that buy large quantities of goods from various producers or vendors, warehouse them, and resell to retailers.

- **Licensed Chemical Sellers**: Facilities registered by the Pharmacy Council to trade in Class B medicines in accordance with the Pharmacy Act (64).

- **Food & Drugs Authority** (FDA) – The main regulator of the Industry. Ensures the adequate standards of safety, efficacy and quality of drugs.

Profile Of Some Players

DASPHARMA

DAS (Dannex Ayrton Starwin) Pharma Plc is a merger of three pharmaceutical manufacturing giants namely Dannex Limited (established 1964), Ayrton Manufacturing Limited (incorporated in 1965) and Starwin Products Limited (formed in 1960). The new merged company was incorporated on December 19, 2019 and subsequently listed on the Ghana Stock Exchange on January 15, 2020 under the trade name DASPHARMA.

It has the largest distribution network in the industry, cutting across the whole country with over 2,000 active wholesale and retail customers in the network with a range of 80 plus products, all manufactured here in Ghana which are categorized as Analgesics, Hermatinics. Anti-tussives, dermatological products, anti-convulsing and anti-asthmatics.

Some of the company's key products include Durol, Virol, Teeder, koffex, ORS, Samalin, Rapinol, Asmadrin and Milk of Magnesia. Most of these products are market leaders in their field and are widely patronized in the country.

The company has a strong Research and Development team which continues to develop cutting edge products for the nation's health needs. The team continually scan the world for international partnerships for technology transfer.

DAS Plc's combined market capitalization would be enough to attract investors to help boost the growth agenda, liquidity and dividend yield to enhance its shareholder value.

Danadams

Danadams was founded in 2005 through the merger of Danpong Pharmaceuticals of Ghana and Adams Pharmaceuticals of China. The Chinese company invested $4million in building a manufacturing plant and 65% of the joint venture's equity, but was bought out by the Ghanaian company in 2006. The company has over 40 products registered in the West African pharmaceutical market.

Danadams focuses on manufacturing prescription anti-malarials, antibiotics for general infections and tuberculosis, and antiretrovirals, all conditions with high prevalence in West Africa. The company also has a few pharmacy branches, which deal with the following insurance programmes: National Health Insurance Scheme, Medex, Momentum, Liberty Health and Managed Health. The branches can also order medicines through a pre-pay scheme.

LaGray Chemical Company

LaGray Chemical Company Limited is a privately held firm, which also has a subsidiary in Illinois, US. LaGray's core competency lies in producing medicines that are specific to the needs of sub-Saharan African countries. It makes essential generic medicines - topical and oral anti-infectives, including treatments for opportunistic infections that arise with malaria or HIV. LaGray is also the first producer of Active Pharmaceutical Ingredients (APIs) in West Africa. It has current Good Manufacturing Practice (GMP) certification and complies with international standards for drug production. Moreover, the company states that it is active in the areas of formulation development, clinical studies, process research and bioequivalence studies.

M&G Pharmaceuticals

Established in 1989, M&G Pharmaceuticals is one of the more prominent domestic pharmaceutical manufacturers. In the same year, the company took over a production site from a division of what is now Unilever Ghana. M&G Pharmaceuticals, which has five production lines, also acts as a drug distributor and wholesaler.

M&G primarily manufactures Products on the Essential Drug published by the Ministry of Health. Its clients are located in all the districts of Ghana with major distributors situated in the regional capitals.

1.4 Pharmaceutical Classifications and Structural Trends

Ghana's pharmaceutical market is among the largest in the West African region. Pharmaceutical sales accounted for 1.16% of GDP and 50.9% of total healthcare expenditure as at 2022. There are two broad categories of medicines which are Prescription medicines and over-the-counter (OTC) medicines. Prescription Medicines can further be divided into two sub sections namely the Patented medicines and Generic medicines.

Figure 2: Categorisation of Medicines

Prescription medicines – Prescription medicines are patented and generic medicines regulated by legislation that requires a physician's prescription before they can be sold to a patient. Prescription medicines dominate the market representing 74.5% by sales value, while OTC medicines occupy a considerably smaller share of 25.5%. The prescription market share is split between patented drugs and generic drugs. Ghana's prescription drug market was valued at GHS5.1bn ($616mn) in 2022. Between 2022 and 2027, Fitch Solutions forecast that Ghana's prescription drug market will grow at local currency compound annual growth rate (CAGR) of 11.0% (US dollar CAGR of 0.6%) to reach GHS8.6bn ($633.0mn) in 2027. Prescription medicines will represent the same total market value by this point, of around 76%. By 2032, they forecast sales of prescription medicines to reach GHS15.1bn ($905.0mn), corresponding to a local currency CAGR of 11.5% (3.9% in US dollar terms) and accounting for 77% of the market value.

Patented and generic drugs sales combined will outpace OTC sales in Ghana, and are set to gain a greater share of the overall pharmaceutical market in the coming years. Population growth, the government's push for wider healthcare coverage and the emergence of chronic lifestyle-related diseases will all drive growth for prescription drugs in Ghana. At the same time, it is expected that domestic manufacturers will increase their drug production. The government is targeting more local companies to gain WHO approval and GMP certification to boost domestic production of essential drugs.

Table 2: Prescription Drug Market Indicators.

PRESCRIPTION DRUG MARKET INDICATORS, HISTORICAL DATA AND FORECASTS (GHANA 2018-2026)

Indicator	2018	2019	2020	2021e	2022f	2023f	2024f	2025f	2026f
Prescription drug sales, GHSbn	1.976	1.808	1.842	1.954	2.083	2.254	2.461	2.709	2.993
Prescription drug sales, GHSbn, % y-o-y	9.64	-8.50	1.88	6.08	6.59	8.19	9.19	10.09	10.48
Prescription drug sales, USDbn	0.431	0.347	0.329	0.329	0.334	0.350	0.372	0.406	0.448
Prescription drug sales, USDbn, % y-o-y	4.03	-19.59	-5.01	-0.08	1.60	4.68	6.47	8.93	10.37
Prescription drug sales, % of total sales	73.4	73.7	74.0	74.2	74.5	74.8	75.0	75.3	75.6

e/f = Fitch Solutions estimate/forecast. Source: United Nations Comtrade Database DESA/UNSD, local news sources, domestic companies, Fitch Solutions

Patented medicines – Patented medicines are innovative medicines granted intellectual property protection by the patent and trademark office. In 2021, Ghana's patented drug market was calculated to have been worth GHS281mn ($47mn), representing 8.3% of the total market value and 11.4% of total prescription sales. This is forecast to reach GHS309mn ($64mn) in 2022 according to Fitch Solutions. Over the long term, the patented drug market is forecast to be worth GHS500mn ($75mn) by 2026, corresponding to a local currency CAGR of 16.1% (14.7% in US dollar terms). By this time, patented drug sales in Ghana will represent a moderately larger 8.29% of the total market value and 11.36% of prescriptions sales - as generic medicines' share of the market increases.

Challenges facing the development of patented market values include the modest pharmaceutical and healthcare funding available to the majority of the population, both through public and private sources. Drug purchasing power remains low, limiting the drive for innovation and lowering Ghana's attractiveness as an export destination for patented drugs. The government's focus on cost containment will act as a stimulus for growth within the generic drugs market, particularly as perceptions of these cheaper medicines and the associated cost benefits improves. Nevertheless, pockets of the more affluent urban population will continue to provide modest opportunities in selected therapeutic areas, including the treatment of chronic diseases, while economic development holds upside potential to stimulate the use of patented drugs in the long term.

Table 3: Patented Drug Market Indicators.

PATENTED DRUG MARKET INDICATORS, HISTORICAL DATA AND FORECASTS (GHANA 2019-2027)									
Indicator	2019	2020	2021	2022	2023f	2024f	2025f	2026f	2027f
Patented drug sales, GHSbn	0.308	0.374	0.592	0.757	0.879	1.008	1.142	1.297	1.474
Patented drug sales, GHSbn, % y-o-y	20.82	21.29	58.44	27.86	16.12	14.70	13.29	13.57	13.65
Patented drug sales, USDbn	0.059	0.067	0.102	0.091	0.073	0.079	0.085	0.098	0.109
Patented drug sales, USDbn, % y-o-y	6.18	13.09	52.71	-10.26	-20.61	9.35	7.32	14.75	11.02
Patented drug sales, % of total sales	9.9	10.3	10.7	11.1	11.5	11.9	12.2	12.6	13.0

f = BMI forecast. Source: United Nations Comtrade Database DESA/UNSD, local news sources, domestic companies, BMI

Generic medicines - A generic drug is identical--or bioequivalent--to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Although generic drugs are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price and they become available after the patent protections afforded to a drug's original developer expires.

According to Fitch Solutions, in 2022, Ghana's generic drugs market was worth GHS4.3bn ($524mn), which represented 63.4% of the total market value and 85.1% of the prescription drug market. This is forecasted to reach GHS4.9bmn ($401mn) in 2023. Generic drug sales will grow at a local currency CAGR of 10.4% over the next five years (US dollar CAGR of 0.9%), to reach a value of GHS7.1bn ($524mn) by 2027, making up a share of 62.8% of the pharmaceutical market in Ghana. In the next ten years, Fitch Solutions forecasts the market to be worth GHS12.2bn (USD730mn) representing a CAGR of 10.9% in local currency terms (3.4% in US dollar terms) and making up 62.2% of the pharmaceutical market.

Our expectation is for actual volumes to potentially rise even more dynamically as generic drug makers increase production to meet rising demand and austerity measures encouraged by the Ghanaian government. Generic prescribing will be promoted as health insurance coverage increases and there are further cost-containment measures enacted by the government, encouraging generic substitution. The United Nations Industrial Development Organisation has created projects to fund the domestic production of essential generic drugs in both Ghana and Kenya, which should help to boost domestic generic drug manufacturing capabilities. Unbranded generics account for approximately 5% of the generic drug market, but this share will gradually increase in the medium to long term.

Table 4: Generic Drug Market Indicators.

GENERIC DRUG MARKET INDICATORS, HISTORICAL DATA AND FORECASTS (GHANA 2019-2027)									
Indicator	**2019**	**2020**	**2021**	**2022**	**2023f**	**2024f**	**2025f**	**2026f**	**2027f**
Generic drug sales, GHSbn	1.990	2.313	3.519	4.336	4.853	5.372	5.882	6.464	7.115
Generic drug sales, GHSbn, % y-o-y	15.61	16.26	52.10	23.22	11.92	10.71	9.49	9.89	10.09
Generic drug sales, USDbn	0.381	0.413	0.606	0.524	0.401	0.423	0.439	0.487	0.524
Generic drug sales, USDbn, % y-o-y	1.61	8.39	46.60	-13.52	-23.48	5.54	3.71	11.03	7.54
Generic drug sales, % of total sales	63.8	63.7	63.6	63.4	63.3	63.2	63.1	62.9	62.8

f = BMI forecast. Source: United Nations Comtrade Database DESA/UNSD, local news sources, domestic companies, BMI

Over-the-counter - A medicine that does not require a prescription to be sold to patients also known as non-prescription medicines.

In 2022, Ghana's OTC drugs market was valued at GHS1.7bn (USD211mn), representing 25.5% of the total market value. Majority of Ghana's population live on low incomes, which correlates to the consumption of OTC medicines. However, the growing popularity of generic medicines will somewhat erode consumption of OTC medicines in Ghana. That said, economic growth and the relative wealth of urban populations will continue to stimulate the segment. Over the medium term, Fitch Solutions forecast the OTC medicine market size to increase to GHS2.7bn ($202mn) by 2027, posting a local currency CAGR of 9.5% (US dollar CAGR of -0.9% contraction). Looking to the long term, Fitch Solutions forecast the OTC market value to reach GHS4.5bn ($269mn) by 2032, for a CAGR of 9.9% in local currency terms (2.5% in US Dollar terms) and representing just 22.9% of the total market value.

The market's development has been hampered by factors such as the lack of healthcare awareness among patients, and continues to suffer from an absence of advertising and consumer-orientated marketing. The OTC sub-sector is further complicated by porous sales channels, a high prevalence of counterfeits, dispensing without prescriptions, sizeable 'grey markets' and widespread use of traditional remedies.

Table 5: OTC Medicine Market Indicators.

OTC MEDICINE MARKET INDICATORS, HISTORICAL DATA AND FORECASTS (GHANA 2019-2027)									
Indicator	**2019**	**2020**	**2021**	**2022**	**2023f**	**2024f**	**2025f**	**2026f**	**2027f**
OTC medicine sales, GHSbn	0.821	0.946	1.426	1.744	1.934	2.123	2.304	2.510	2.739
OTC medicine sales, GHSbn, % y-o-y	14.58	15.21	50.71	22.26	10.95	9.74	8.53	8.93	9.12
OTC medicine sales, USDbn	0.157	0.169	0.246	0.211	0.160	0.167	0.172	0.189	0.202
OTC medicine sales, USDbn, % y-o-y	0.70	7.42	45.26	-14.20	-24.15	4.62	2.81	10.06	6.60
Over-the-counter (OTC) medicine sales, % of total sales	26.3	26.0	25.8	25.5	25.2	25.0	24.7	24.4	24.2

1.5 Industry Size

Pharmaceutical Market

Pharmaceutical sales in Ghana reached GHS6.8bn ($826mn) in 2022, and this is forecast to rise to GHS7.7bn ($634mn) in 2023. Looking further forward, by 2027 we expect sales to achieve a compound annual growth rate (CAGR) of 10.6% in local currency (0.2% in US dollars) to GHS11.3bn ($835mn). By the end of the 10-year period Fitch Solutions forecasts sales to reach GHS19.6bn (USD 1.2bn) by 2032 corresponding to local CAGR of 11.1% (3.6% in US Dollar terms). This healthy growth rate is characteristic of many pharmaceutical markets in Sub-Saharan Africa, where robust growth in medicine sales will be driven mainly by increased volume consumption within the generic medicines sub-sector. Across the region, generic drug makers will increase production to meet the rising demand which will be boosted by cost-containment measures encouraged by governments. Per capita spending on medicines will increase from $25 in 2022 to $29 by 2032, remaining low by global standards. Pharmaceutical spending as a percentage of GDP will decrease gradually over the forecast period from 1.2% in 2022 to 0.7% in 2032.

Figure 3: Pharmaceutical Supply Chain



Source: Fitch Solutions

Table 6: Pharmaceuticals Sales and Forecasts

PHARMACEUTICAL SALES, HISTORICAL DATA AND FORECASTS (GHANA 2019-2027)									
Indicator	**2019**	**2020**	**2021**	**2022**	**2023f**	**2024f**	**2025f**	**2026f**	**2027f**
Pharmaceutical sales, GHSbn	3.119	3.633	5.537	6.836	7.666	8.503	9.328	10.270	11.328
Pharmaceutical sales, GHSbn, % y-o-y	15.83	16.48	52.39	23.47	12.14	10.92	9.70	10.10	10.30
Pharmaceutical sales, GHS per capita	99.0	112.9	168.6	204.2	224.7	244.5	263.2	284.5	308.1
Pharmaceutical sales, USDbn	0.598	0.649	0.954	0.826	0.634	0.670	0.696	0.774	0.835
Pharmaceutical sales, USDbn, % y-o-y	1.80	8.60	46.88	-13.35	-23.33	5.75	3.92	11.25	7.75
Pharmaceutical sales, USD per capita	19.0	20.2	29.0	24.7	18.6	19.3	19.6	21.5	22.7
Pharmaceutical sales, % of GDP	0.87	0.93	1.21	1.16	0.97	0.91	0.88	0.85	0.82
Pharmaceutical sales, % of health expenditure	35.7	37.8	50.0	50.9	51.2	50.1	49.2	48.5	47.8

f = BMI forecast. Source: United Nations Comtrade Database UNSD/DESA, ITC, local news sources, domestic companies, BMI

Ghana has growing influence in the Economic Communities of West African States (ECOWAS). Ghana is attempting to fulfil its ambition of being the ECOWAS' hub for pharmaceutical investment. During the 83rd annual general meeting of the Pharmaceutical Society of Ghana in August 2018, Bawumia disclosed several interventions by the government to support domestic drugmakers, some of which are already underway, including:

- Exempting select imported pharmaceutical products from VAT.
- Expanding of the list of raw materials exempt from VAT to accommodate inputs to support the local pharmaceutical manufacturing industry.
- Providing additional funding to some local pharmaceutical companies to build new production plants and raise their standard of production towards international quality standards. The provisions will be made by Exim Bank Ghana.

In addition to these measures, Ghana's Ministry of Foreign Affairs and the Ministry of Trade and Industry are attempting to remove trade barriers and promote Ghanaian pharmaceutical products within the ECOWAS region. Moreover, a framework is currently being designed that ensures Ghana's Ministry of Health procures more locally manufactured medicines, the government is looking to allocate a designated pharmaceutical manufacturing zone, as well as reforming the national health insurance scheme.

Healthcare Expenditure

Healthcare expenditure in Ghana as at 2021 stood at a GHS14.454bn ($2.433bn). This increased to GSH16.061bn (USD2.577bn) in 2022 according to Fitch Solution forecast. Looking to 2026, healthcare expenditure is anticipated at a compound annual growth rate (CAGR) of 7.3% in local currency (8.3% in US dollar terms) to GHS24.5bn ($3.7bn). Private spending accounts for 55% of the market but is projected to grow at an average faster rate than government spending (13.7% vs 7.4% in local currency). While total health expenditure is expected to almost double in the long term, annual per capita spending will post a much lower growth rate, increasing from $77.0 in 2021 to $104.4 by 2026.

There is limited uptake of advanced pharmaceuticals, medical devices and procedures in Ghana. This is due to a modest government health budget and low consumer spending power. There are insufficient numbers of healthcare facilities, especially modern hospitals, to meet demand. These facilities are often poorly equipped with medical devices. There is also a shortage of health professionals. Quality of care is much lower in rural areas compared with the cities. Like other countries in sub-Saharan Africa, many Ghana-trained doctors, nurses and pharmacists emigrate to higher income countries.

Ghana's once-celebrated National Health Insurance Scheme (NHIS) will continue to face challenges, especially financing issues. While enrolment numbers have climbed in recent years, the scheme suffers from an insufficient subsidy base. The NHIS also does not cover all diseases, and often only covers part of the overall care for a patient. It is a long term goal to achieve universal healthcare coverage in Ghana. It has been proposed that the NHIS adopts advanced healthcare management tools such as strategic purchasing and health technology assessment.

Government support for healthcare is good by regional standards but Ghana still relies on external stakeholders for many aspects of the provision of medical services. For example, the United States Agency for International Development (USAID) recently completed a 5-year project with Ghana's government and other partners to improve fundamental aspects of the health system. China has provided specialist surgeons to improve capabilities in Ghana, and also trained Ghanaian doctors in China.

Table 7: Healthcare Expenditure Trends

HEALTHCARE EXPENDITURE TRENDS, HISTORICAL DATA AND FORECASTS (GHANA 2018-2026)

Indicator	2018	2019	2020	2021e	2022f	2023f	2024f	2025f	2026f
Health spending, GHSbn	10.638	11.736	13.084	14.454	16.061	17.839	19.816	22.006	24.481
Health spending, GHSbn, % y-o-y	25.79	10.33	11.48	10.47	11.11	11.08	11.08	11.05	11.24
Health spending, GHS per capita	357.4	385.8	421.1	455.5	495.8	539.6	587.4	639.6	697.7
Health spending, USDbn	2.320	2.249	2.338	2.433	2.577	2.769	3.000	3.296	3.663
Health spending, USDbn, % y-o-y	19.34	-3.04	3.94	4.06	5.92	7.47	8.31	9.89	11.13
Health spending, USD per capita	77.9	74.0	75.2	76.7	79.5	83.8	88.9	95.8	104.4
Health spending, % of GDP	3.55	3.35	3.23	3.28	3.17	3.06	2.93	2.83	2.74

e/f = Fitch Solutions estimate/forecast. Source: WHO, Fitch Solutions

GOVERNMENT HEALTHCARE EXPENDITURE TRENDS, HISTORICAL DATA AND FORECASTS (GHANA 2018-2026)

Indicator	2018	2019	2020	2021e	2022f	2023f	2024f	2025f	2026f
Govt. health spend, GHSbn	4.770	5.128	5.630	6.036	6.539	7.056	7.586	8.117	8.685
Govt. health spend, GHSbn, % y-o-y	36.22	7.50	9.80	7.20	8.34	7.90	7.51	7.00	7.00
Govt. health spend, USDbn	1.040	0.983	1.006	1.016	1.049	1.095	1.148	1.216	1.300
Govt. health spend, USDbn, % y-o-y	29.25	-5.52	2.38	0.97	3.27	4.40	4.83	5.88	6.89
Govt. health spend, % total health spend	44.84	43.69	43.03	41.76	40.72	39.55	38.28	36.89	35.48

e/f = Fitch Solutions estimate/forecast. Source: WHO, Fitch Solutions

PRIVATE HEALTHCARE EXPENDITURE TRENDS, HISTORICAL DATA AND FORECASTS (GHANA 2018-2026)

Indicator	2018	2019	2020	2021e	2022f	2023f	2024f	2025f	2026f
Private health spend, GHSbn	5.868	6.609	7.453	8.418	9.521	10.783	12.230	13.889	15.795
Private health spend, GHSbn, % y-o-y	18.41	12.63	12.79	12.94	13.10	13.26	13.41	13.57	13.72
Private health spend, USDbn	1.280	1.267	1.332	1.417	1.528	1.674	1.851	2.080	2.363
Private health spend, USDbn, % y-o-y	12.35	-1.02	5.16	6.38	7.81	9.58	10.58	12.38	13.61
Private health spend, % total health expenditure	55.16	56.31	56.97	58.24	59.28	60.45	61.72	63.11	64.52

1.6 Pricing Structure

The National Health Insurance Act has made provisions to provide cost exemptions for medicines. Patients who cannot afford medicines, children under five, pregnant women and elderly persons are provided with medicines free of charge. Some medicines are provided publically at no cost which includes all medicines in the Essential Medicines List (EML) and medicines for the treatment of malaria, any non-communicable disease, tuberculosis, HIV/AIDS, sexually transmitted diseases and immunisation vaccines for children.

Ghana has been ranked as the country with one of the highest medicine prices in Africa. The country imports around two-thirds of its medicines, thus contributing to the high pricing of drugs, according to the WHO's Medicine Price component study. The WHO's office in Ghana has urged the government to reinstitute rebates on medicine taxes in order to boost local pharmaceutical production. Ghana's parliament passed the value-added tax amendment bill in 2017, which stipulates that certain pharmaceuticals and selected active ingredients and inputs for the manufacture of pharmaceuticals are exempt from tax. The aim of the bill is to minimise healthcare costs in Ghana and support local drug companies attempting to achieve economies of scale.

The introduction of the National Health Insurance Scheme intended to give more autonomy to drug purchasers across the country. In practice, however, this is not always adhered to and markups have been reported to be significantly higher than 10%, increasing consumer prices and restricting sales. Due to the levels of wealth inequality across the population, pharmaceutical demand is predominantly influenced by drug pricing. Reimbursed drugs have seen prices frozen in Ghana over the past few years, rather than receiving biannual increases. The decision to include cancer treatments on the national health insurance scheme will increase opportunities for foreign drug makers in Ghana.

In July 2019, the Ministry of Health in Ghana established a National Medicine Price Committee. The organisation will set the public and private maximum sale prices of essential medicines (including those in the Ghana National Drugs Programme), single-source products, patented medicines and other health technologies. It is also responsible for calculating the maximum reimbursement prices for all medicines, and to provide a buffering mechanism against exchange rate fluctuations. The committee is comprised of stakeholders from the Ministry of Finance, the Ghana Revenue Authority, the Ghana Health Service, the National Health Insurance Authority, the Regional Medical Stores, the Ghana Chamber of Pharmacy, the Pharmaceutical Manufacturers Association of Ghana and the WHO.

It is hoped that the National Medicine Price Committee will increase the affordability of medicines in Ghana. Like in many other low income countries, branded generics are very popular in Ghana. This is due to the distrust of commoditised unbranded generic drugs, which are often seen by patients as poor quality. The downside of branded generics is that they can incur a significant price premium, especially if they are sourced from developed states. Even cheaper branded generics from India are often unaffordable for many patients and institutional payers in Ghana.

It is also anticipated that the organisation will boost the attractiveness of the market to local and foreign drug makers. A more stable pharmaceutical pricing environment should boost volume sales, and therefore increase revenue and profit for manufacturers. It should also reduce debts owed by health facilities to suppliers. More medicine pricing transparency should also lower the reports of healthcare corruption. A cap on patented drug prices will however not be welcomed by foreign multinationals.

1.7 Supply/Distribution Dynamics

Pharmaceutical products are either manufactured locally or imported into the country. In some cases, just the raw materials are imported but the finished products are made here in Ghana.

The hub of the pharmaceutical wholesale market is the Accra suburb of Okashie, though other major towns like Kumasi and the twin-city of Sekondi and Takoradi have relatively smaller hubs of wholesalers. There are 35 registered pharmaceutical manufacturers in Ghana and these companies serve the hundreds of pharmaceutical wholesalers directly. Some of the pharmaceutical producers have their own wholesale stores in Accra and other cities. Pharmaceutical wholesalers supply products to both the public and private sectors.

The Public Sub-sectors

The public pharmaceutical sub-sector comprises of the Central Medical Stores (CMS) under the Ministry of Health, that is the central wholesaler and the regional medical stores that supplies pharmaceuticals to the health facilities. The CMS sources its supplies from both local and foreign manufacturers. In the distribution of pharmaceutical products in the public sector, in the case of stock outs or limited access to medicines at regional medical stores and service delivery points, they are permitted to purchase products from the private sector.

The Private sub-sector

Customers from the private sector can be classified into three main groups as follows: (1) registered pharmacies; (2) chemical sellers; and (3) direct consumers. Registered pharmacies, which number over 1,000 in Ghana, – often source their products from pharmaceutical wholesalers or sometimes directly from producers in Ghana and/or overseas especially India. Chemical sellers are more likely to get their products directly from pharmaceutical wholesalers and major retailers in big cities and towns. In a few cases, consumers of pharmaceutical products directly buy their products from pharmaceutical wholesalers. The direct buyers are likely to be people knowledgeable in the science of pharmacy or medicine.

Unichem is one of the more prominent pharmaceutical distributors in Ghana. The company deals in prescription drugs (branded and generic varieties) as well as hospital supplies. Unichem distributes imported products from the UK, India and Germany in Ghana and in Nigeria.

On the retail side, the Pharmacy Council is responsible for registration. Pharmaceutical chains are not common, with most consisting of fewer than 10 stores, although this is expected to change as the pharmaceutical market develops. Some of the retail chains - including Kama Group, Kinapharma and Ernest Chemists - have developed wholesaling activities and have become engaged in pharmaceutical manufacturing. Kinapharma, for example, produces a range of OTCs as well as prescription medicines. Kama deals in distribution of products manufactured by foreign companies such as Spanish Almiral Prodesfarma and Indian XL Laboratories PVT, and also operates a number of health clinics.

It is also worth noting that the Christian Health Association of Ghana (CHAG) runs a central warehouse in Accra, the Catholic Distribution Centre (CDC) in the distribution of drugs.

1.8 Demand Dynamics

The demand for pharmaceutical products in Ghana is clearly competitive, with many retailers and consumers e.g. hospitals, pharmacy stores, health care centers, clinics, individuals. The demand for pharmaceutical products in Ghana has been influenced by economic factors such as incomes and increasing populations and specific government policies. Pharmaceutical sales through hospitals, retail pharmacies and other channels in 2021 was GHS 2.6 billion representing 0.60% of GDP. This is projected to close at GHS2.8 billion by 2022. The demand for pharmaceutical products in the short to medium term will be mainly driven by the following factors:

- Ghana's sizeable population to support large-scale drug manufacturing.
- Disease burden drives high demand for HIV/AIDS, tuberculosis and malaria medicines.
- Modernisation of local healthcare facilities.
- New hospitals scheduled to be built in Ghana.
- Expansion of health insurance.

The four (4) main factors that drive the purchase of a particular drug in relation to direct consumers are:

i. Affordability: people usually want to pay for drugs that are not expensive.
ii. Effectiveness: consumers would always want to buy a drug that really works.
iii. How well known the brand is: majority of people are scared to use a drug they haven't heard so much about.
iv. Doctor's prescription – once it's prescribed by the physician then it's won the consumers trust because patients usually go with the doctor's advice.

1.9 Production Dynamics

Figure 4: Production Process



Pharmaceutical manufacturing is one of the most vibrant components of the manufacturing sector of the Ghanaian economy. Manufacturing of medicines has been in existence in Ghana for more than 50 years. Over these years, there has been a gradual yet consistent improvement in the pharmaceutical manufacturing sector in Ghana both in quality and quantity of medicines produced.

According to the ECOWAS secretariat, within the sub region, Ghana currently has the best quality of locally produced pharmaceuticals due to the stringent criteria, inspection and enforcement procedures of the Ghana Food & Drugs Authority (FDA) and the recent efforts made by local manufacturers to meet the FDA requirements.

Ghana’s pharmaceutical manufacturing sector currently comprises 36 registered firms, employing a wide range of professionals including pharmacists, chemists, engineers and technologists. More than 75% of the companies are owned by Ghanaian entrepreneurs.

The local industry has an installed capacity for both solid and liquid dosage forms to supply all domestic needs as well as enough for export. There is however capacity underutilization (less than 55% on the average) as a result of inadequate resources. The Ghanaian pharmaceutical market is made up of approximately 30% locally produced and 70% imported products. (The latter originating mainly from India and China).

Below is a list of some of the major manufacturing copanies under the Pharmaceutical Manufacturers Association of Ghana.

- African Global Pharma (Gh) Ltd
- Amponsah Efah Pharmaceuticals
- Daspharma Manufacturing Ltd
- Danadams Pharmaceuticals Ltd
- Annex Limited
- Ernest Chemist Ltd
- Eskay Therapeutics Ltd
- Gr Pharma
- Intravenous Infusions Ltd
- Kama Industries Ltd
- Kanbros Chemical Industries
- Pokupharma Limited
- New Global Pharmaceuticals
- Sanbao Pharmaceutical Ltd
- Dannex
- Lagray Chemical Company
- M&G Pharmaceuticals Ltd
- Midland Pharmaceuticals Ltd
- Pam Pharmaceuticals Ltd
- Perfect Pharmaceuticals Ltd
- Pharmanova Ltd
- Phyto-Riker (Gihoc) Pharmaceuticals
- Sharp Pharmaceuticals
- Starwin Products
- Unichem Industries
- Letap Pharmaceuticals
- Aspee Pharmaceuticals Ltd
- Entrance Sci.Research Centre
- Kinapharma Ltd
- Tobinco Pharmaceuticals

1.10 Regulatory Dynamics

The pharmaceutical regulatory environment in Ghana is governed by the Food and Drugs Authority (FDA). The Ghanaian FDA has its own drug-testing facilities which test medicines as part of its post-marketing surveillance strategy. The Ghanaian FDA is segmented. The registration and inspectorate division is responsible for the evaluation of medicine registration applications leading to the registration of medical products. The safety monitoring and clinical trials division ensures the safety of regulated products from the Public Health Act. In recent years, as Ghana has established a more rigorous regulatory environment, this has enabled the government to support local drug makers as well as limited foreign direct investment (FDI).

Ultimately, streamlined regulatory processes should increase access to medicines. Moreover, the drug registration process in Ghana takes between six and 18 months, which is relatively short compared with other countries in Africa. The high costs of borrowing and,
therefore, doing business in the country coupled with the low purchasing power of patients severely limits returns and deters Foreign Direct Investment (FDI). Local drug makers have also begun upgrading facilities to meet with international Good Manufacturing Practice standards.

Meanwhile, regulatory approval processes for generic medicines should be revised to ensure that medicines that could be cost-effective and easily produced are not being prevented from reaching the market by bureaucracy, though this must be done without compromising safety. It is worth noting that Ghana's proximity to Nigeria - as well as to other West African neighbours with less stringent regulatory practices - places it on an ideal transit route for illegal drug and counterfeit trafficking. Therefore, the activities of its regulatory body are even more significant for the development of its domestic drug market. Moreover, regulatory improvements would likely give a boost to the patented drugs market in Ghana.

Regional Progress

The Pharmaceutical Manufacturers Association of Ghana (PMAG) has proposed that a regional pharmaceutical regulatory body within the Economic Community of West African States (ECOWAS) would increase access to medicines and allow pharmaceutical firms to grow. However, poor border controls and weak drug regulations in other ECOWAS states mean regional harmonization remains a long way off. Nevertheless, this does not reflect badly on Ghana's pharmaceutical industry, or indeed its capacity for expansion within West Africa. Complying with Trade Related Aspects of Intellectual Property Rights (TRIPS) will invite multinational drug makers looking for joint ventures or licence agreements in Ghana. PMAG has highlighted this, particularly in light of loopholes that exist within the regulatory criteria in the country. In the long run, this would allow medicine manufacturers to export higher volumes of pharmaceuticals within and beyond West Africa.

Intellectual Property Issues

Ghana is a member of the WTO and legal provisions do exist for granting patents to manufacturers. Intellectual property (IP) rights in the country are managed and enforced by the Patent Office, Registrar General's Department. There are no legal provisions for data exclusivity for pharmaceuticals, patent extension or patent status and marketing authorisation.

Despite the presence of a patent office, the law governing IP is fragmented across various sectors, including the pharmaceutical sector. A draft IP legislation designed to harmonise the laws on IP has been created, which also hopes to reduce counterfeit products on the Ghanaian market and boost investor confidence in doing business in Ghana. However, limited progress has been made to suggest the IP reform has been hugely successful.

The most recent revisions of intellectual property laws between 2000 and 2006 have brought Ghana's legislation into compliance with the TRIPS. However, it is yet to amend all relevant laws to bring the country into full compliance. For the most part, Ghana continues to use the rules and regulations promulgated for previous laws, which often results in a disconnection of procedure and enforcement.

Pharmacovigilance

There are no legal provisions in the Ghanaian Medicines Act providing for pharmacovigilance activities as part of the Medicines Regulatory Agency (MRA) mandate. Legal provisions do not exist that require the marketing authorisation holder to continuously monitor the safety of their products and report to the MRA. There are no laws regarding the monitoring of adverse drug reactions. In June 2019, the mobile app 'Med Safety' was launched to enable both healthcare professionals and patients to report side effects to the FDA. The app was developed in collaboration with the government of Japan, the WHO and other stakeholders.

1.11 Trade Dynamics

As with most emerging African countries, Ghana has a negative trade balance in relation to pharmaceutical trade. According to the Ghana Health Service, only 30% of the national requirements of pharmaceutical products are produced in Ghana, while the remaining 70% are imported. However, the Ghanaian government has emphasized the need to manufacture more locally produced medicines over the next decade, an ambition it shares with many African governments.

Ghana's pharmaceutical trade performance is relatively erratic. Although its few key local drug makers are known to produce essential medicines for local demand and exports, data from the United Nations Trade Database suggest an unpredictable output. Pharmaceutical imports were estimated at GHS3.19bn (USD386mn) in 2022. Fitch Solutions forecast this to reach GHS3.58bn (USD296) by 2023. Most pharmaceutical imports, predominantly low-value generic drugs, come from India, China and the EU. Increasing access to medicines will raise demand for drugs and therefore imported products, while local manufacturing also expands due to European funding and domestic political and industry support.

Exports are forecast to increase from GHS59.36mn in 2022 to GHS112.47mn by 2023. This is projected to reach GHS190.38mn by 2026. This increase is faster than that of imports, which are expected to develop at a considerable pace over the forecast period by Fitch Solutions (See Table 8), albeit from a much lower base. The positive outlook by Fitch Solution for Ghana's exports over the next five years is based on the increased output and efficiency of local drugmakers and continental acquisitions (including South African Adcock Ingram's recent foray in the country to purchase Ghanaian Ayrton Drug Manufacturing). Ghanaian drugmakers are focusing on gaining Good Manufacturing Practice certification to boost export potential.

Figure 5: Trade of Pharmaceutical Products



Source: BMI

Table 8: Pharmaceutical Trade Data & Forecast

PHARMACEUTICAL TRADE DATA AND FORECASTS (GHANA 2021-2027)							
Indicator	**2021**	**2022**	**2023f**	**2024f**	**2025f**	**2026f**	**2027f**
Pharmaceutical exports, USDmn	10.41	7.18	9.30	9.92	11.14	12.21	13.44
Pharmaceutical exports, USDmn, % y-o-y	247.13	-31.10	29.54	6.69	12.34	9.62	10.02
Pharmaceutical imports, USDmn	445.04	385.64	295.66	312.64	324.88	361.43	389.45
Pharmaceutical imports, USDmn, % y-o-y	46.88	-13.35	-23.33	5.75	3.92	11.25	7.75
Pharmaceutical trade balance, USDmn	-434.62	-378.46	-286.36	-302.73	-313.74	-349.22	-376.01

f = BMI forecast. Source: United Nations Comtrade Database DESA/UNSD, BMI

PHARMACEUTICAL TRADE DATA AND FORECASTS, LOCAL CURRENCY (GHANA 2021-2027)							
Indicator	**2021**	**2022**	**2023f**	**2024f**	**2025f**	**2026f**	**2027f**
Pharmaceutical exports, GHSmn	60.46	59.36	112.47	125.87	149.28	161.95	182.40
Pharmaceutical exports, GHSmn, % y-o-y	260.16	-1.82	89.48	11.91	18.59	8.49	12.63
Pharmaceutical imports, GHSmn	2,583.76	3,190.16	3,577.45	3,968.11	4,353.02	4,792.67	5,286.31
Pharmaceutical imports, GHSmn, % y-o-y	52.39	23.47	12.14	10.92	9.70	10.10	10.30
Pharmaceutical trade balance, GHSmn	-2,523.30	-3,130.81	-3,464.98	-3,842.24	-4,203.74	-4,630.72	-5,103.92

f = BMI forecast. Source: United Nations Comtrade Database DESA/UNSD, BMI

1.12 Foreign Exchange Dynamics

Availability of forex is key to this sector because 70% of pharmaceutical products are imported into the country. The players in this sector source for foreign exchange for the importation of needed raw materials and finished products through their local bank. As the sector generates most of its revenues in Cedis, fluctuations in exchange rate affects cost of sales. The key players because of exposure to volatility in local currency to foreign currencies especially the dollar use derivative hedging strategies and engage also in forward contracts to minimize the effect of currency fluctuations. The sector requires over $200 million in FX annually.

1.13 Margin Structure

As per figure 6 below, the sector records high margins on its sales with gross profit margins hovering around 52% as at 2022. Administrative expenses constituted 33.2% of revenue respectively in 2022 and thus the negative operating profit margin in 2022.

Figure 6: Profit Margins



Source: Audited Financial Reports of Major Players, GCB Strategy & Research Estimates

1.14 Asset Composition

The industry is largely driven by Property, plant and equipment on one hand and inventories on the other hand. This is partly due to its strategic function of not risking running out of key drugs as well as cushioning against future price hikes. As at 2022, inventories formed 33.5% of industry assets. Plants and equipment formed 32.4% of the total assets. Trade and other receivable constituted 20.8% whilst others (investment and cash and bank) represented 13.2%. Figure 7 below shows the assets composition of major players in the pharmaceutical industry for 2022.

Figure 7: Assets Composition 2022



Financial Reports of Major Players, GCB Strategy & Research Estimates

1.15 Financing Model

The industry requires quick turnover of funds and this is depicted in its financing structure. As per figure 8 below, the industry relies on both interest-bearing and non-interest bearing financing. Majority of its operations as at end of 2022 was funded from non-interest-bearing liabilities i.e. deferred tax and accounts payable making 47.9% of the financing structure comprising credit purchases. The interest-bearing financing comprise of short (working capital) and long-term borrowings constituting 45.9% and lastly equity which is 6.2%.

Figure 8: Financing Structure



Source: Audited Financial Reports of Major Players, GCB Strategy & Research Estimates

Financing model applicable to each phase of the value chain

Table 9: Financing Model

Value Chain Phase	Applicable Financing Model
Inbound Activities	• Supplier Credit • Short term facilities • Letters of Credit • Working Capital Facilities • Shareholder's Funds
Processing/Operations	• Share Capital • Shareholder's Funds • Supplier Credits • Long tenured facilities
Outbound Activities	• Short term facilities

1.16 Risk Consideration in the Sector

Some of the risks associated with this sector include:

- The high cost of borrowing.
- Lack of access to investment or developmental capital.
- Inadequate human resource availability.
- Importation of cheaper sub-standard drugs.

- Counterfeiting.
- Limited government contribution to healthcare.
- Low income status of citizens –requiring low affordability levels.
- Lack of healthcare awareness among patients.
- Absence of advertising and consumer-orientated marketing.
- Lack of access to land specifically earmarked for pharmaceutical production. Pharmaceutical industries, due to the level of quality required especially to attain W.H.O. Prequalification, are to be located in areas where there are or will be no contamination whatsoever from any other industry.

1.17 Key Success Factors

Ghana's pharmaceutical market is among the largest in the West African region. The growth of the Pharmaceutical market is expected to be driven by:

- Research and Development.
- Disease burden.
- Brand/product visibility.
- Innovation.
- Wide and effective distribution network.
- Cost effective production process.
- Supply chain efficiency.
- Access to finance.
- Quality Control.
- Proper regulation.
- Sizable population growth to support pharmaceutical expenditure growth.
- Domestic drug makers gaining support towards achieving WHO qualification and GMP certification.

1.18 Key Banking Expectations, Banking Needs - Current and Potential

Some of the key Banking Expectations of the Pharmaceutical sector includes:

- Good knowledge of international trade.
- Capacity to fund large ticket transactions.
- Efficient technology platforms
- Easy access to Foreign Exchange

Key Banking Needs Structed according to Value Chain Phase

Table 10: Banking Needs

VALUE CHAIN PHASE	NEEDS	TYPE OF FINANCE
Inbound Activities	Raw Materials Local	· Short term finance
		· Supplier finance
	Raw Material Import Importation of Equipments	· Trade finance (letters of credit)
		· FX purchase
Operations	Expansion	· Long term finance/ Commercial finance (factory)
	Capital Expenditure	· Equipment finance
	Spare parts	· Trade finance.
	Maintenance	· Short term finance
	Operating expenses	· Working Capital finance
	Vendor financing	· Working Capital finance.
	Employees	· Consumer loans
		· Payroll management
Outbound Activities	Distributors	· Distributor finance
		· Inventory finance
		· Property (warehouse) financing
	Marketing/ Advert Cost	· Invoice discounting (for vendor)

1.19 Conclusion/Outlook

Ghana's pharmaceutical market is among the largest in the West African region. The total pharmaceutical sales recorded for 2022 was GHS6.836bn ($826mn) representing 1.16% of GDP, and this is forecast to rise to GHS7.666 in 2023. Pharmaceutical sales accounted for 50.9% of total healthcare expenditure in 2022 and Fitch Solutions projects it to rise to 51.2% in 2023.

Government is beginning to focus on prevention rather than treatment, although they have not yet invested very much in pre-emptive measures and regulators are also becoming more cautious about approving truly innovative medicines. Ghana has been ranked as the country with one of the highest medicine prices in Africa. The country imports around 70% of its medicines, contributing to the high pricing of drugs, according to the WHO's Medicine Price component study. Increased research and development, Government policies as well as growth in pharmaceutical manufacturing in Ghana should make pharmaceutical products affordable for all in the coming years.

The increasing instances of chronic diseases will place even greater pressure on already stretched healthcare budgets. Ghana's gradual expansion of health coverage with the building of new hospitals coupled with modernization of local healthcare facilities will translate into rising demand for medical treatment. Disease burden will also drive high demand for HIV/AIDS, tuberculosis and malaria medicines. Generic medicines will remain dominant given low affordability as well as limited local drug manufacturing capacity. On the other hand, high cost of borrowing, importation of cheaper sub-standard drugs as well as counterfeiting continues to pose great risks to the pharmaceutical industry.

Annex 1: List of Foreign Manufacturing Facilities

MANUFACTURING FACILITIES DEPARTMENT

LIST OF LICENSED FOREIGN PHARMACEUTICAL MANUFACTURING FACILITIES AS AT JULY 2022

VALID LICENCES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
1	CZECH REPUBLIC	**FERRING LECIVA, A.S**	K RYBNIKU 475 252 42 JESENICE U PRAHY, CZECH REPUBLIC	ENEMA	FDA/GMP/001/01/18	**October-22**
2	BULGARIA	**SOPHARMA PHARMACEUTICALS LIMITED**	16, LLIENSKO SHOSE STREET, 1220 SOFIA, BULGARIA	ORAL SOLIDS (TABLETS AND CAPSULES), INJECTABLES	FDA/GMP/002/01/18	**October-22**
3	USA	**ALOE VERA OF AMERICA, INC**	13745 JUPITER ROAD, DALLAS TEXAS 75238, U.S.A.	ORAL LIQUIDS (FOOD SUPPLEMENTS)	FDA/GMP/015/01/19	**February-23**
4	INDIA	**NATCO PHARMA LIMITED**	PHARMA DIVISION, KOTHUR-509 228, RANGER REDDY DISTRICT, TELENGANA -INDIA	ORAL TABLETS, ORAL CAPSULES	FDA/GMP/009/01/19	**June-23**
5	INDIA	**NEM LABORATORIES PVT LIMITED**	PLOT NO. 133, KRISHNA INDUSTRIAL ESTATE, VASAI-EAST, THANE, MAHARASHTRA, INDIA	ORAL TABLETS, TOPICAL PREPARATIONS	FDA/GMP/002/11/18	**June-23**
6	INDIA	**SAGA LABORATORIES LIMITED**	SURVEY NUMBER 198/2,-198/3, CHACHRAWADI VASNA, TA:SANAND, DISTRICT AHMEDABAD-INDIA	ORAL TABLETS (COATED AND UNCOATED), ORAL CAPSULES (HARD GELATINE), DRY POWDERS, BETA LACTAMS	FDA/GMP/013/01/19	**June-23**
7	BELGIUM	**GLAXOSMITHKLINE BIOLOGICALS SA**	PARC DE LA NOIRE EPINE, RUE FLEMMING 20, WAVRE 1300, BELGIUM	VACCINES	FDA/GMP/005/01/19	**August-23**
8	NIGERIA	**GLAXOSMITHKLINE NIGERIA PLC LIMITED**	KM 32, IGBESA ROAD, AGBARA INDUSTRIAL ESTATE, AGBARA, OGUN STATE - NIGERIA	ORAL TABLETS AND CAPLETS, EFFERVESCENCE POWDERS,	FDA/GMP/006/01/19	**August-23**
9	SWEDEN	**Q-PHARMA CONTRACT DEVELOPMENT AND MANUFACTURING, AB**	AGNESLUNDSVAGEN 27, 212 15 MALMO, SWEDEN	PESSARIES, ORAL LIQUIDS, POWDERS AND SOLID DOSAGE FORMS	FDA/GMP/012/01/19	**August-23**
10	USA	**ABBVIE INC**	NORTH CHICAGO FACILITY 1401 SHERIDAN RD. NORTH CHICAGO IL 60064-4000, USA	SMALL VOLUME PARENTERALS	FDA/GMP/001/01/19	**September-23**
11	USA	**ASTRAZENECA PHARMACEUTICALS LP**	4601 HIGHWAY 62 EAST, MT. VERNON, IN 47620-1500, USA	ORAL TABLETS,ORAL CAPSULES, POWDER FOR ORAL SUSPENSION,ORAL LIQUIDS	FDA/GMP/002/01/19	**September-23**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
12	THAILAND	**MEGA LIFESCIENCES PUBLIC COMPANY LIMITED**	515/1 SOI 8, 384 SOI 6, BANGPOO INDUSTRIAL ESTATE, PATTANA 3 ROAD, MUEANG, SAMUTPRAKARN 10280, THAILAND	ORAL TABLETS, EFFERVESCENCE POWDERS, ORAL CAPSULES (HARD AND SOFT)	FDA/GMP/008/01/19	**September-23**
13	INDIA	**BIOLOGICAL E. LTD**	PLOT NO.1, S.P. BIOTECHNOLOGY PARK, PHASE II, KOLTHUR (V), SHAMEERPET (M), RANGA REDDY (DIST.) TELANGANA, INDIA.	SMALL VOLUME PARENTERALS	FDA/GMP/003/01/19	**October-23**
14	FRANCE	**CENEXI S.A.S**	52,RUE MARCEL ET JACQUES GAUCHER, 94120 FONTENAY-SOUS-BOIS CEDEX , FRANCE	ORAL TABLETS,ORAL CAPSULES, PARENTERALS, ORAL LIQUIDS	FDA/GMP/004/01/19	**October-23**
15	FRANCE	**LES LABORATOIRES SERVIER INDUSTRIE**	905 ROUTE DE SARAN 45520 GIDY, FRANCE	ORAL SOLID DOSAGE FORMS	FDA/GMP/007/01/19	**October-23**
16	INDIA	**VINS BIOPRODUCTS LIMITED**	SURVEY. NO. 117, THIMMAPUR VILLAGE, KOTHUR MANDAL,RANGAREDDY DISTRICT-509325, TELANGANA, INDIA	PARENTERALS	FDA/GMP/014/01/19	**October-23**
17	INDIA	**CACHET PHARMACEUTICALS PVT. LIMITED**	VILLAGE & POST - THANA (BADDI) DISTRICT-SOLAN, HIMACHAL PRADESH-173 205, INDIA	ORAL TABLETS, ORAL CAPSULES,ORAL LIQUIDS, DRY POWDWES	FDA/GMP/017/02/19	**October-23**
18	INDIA	**INDCHEMIE HEALTH SPECIALTIES PRIVATE LIMITED**	VILLAGE & POST - THANA (BADDI) DISTRICT-SOLAN, HIMACHAL PRADESH-173 205, INDIA	ORAL TABLETS, ORAL CAPSULES, POWDER FOR ORAL SUSPENSION	FDA/GMP/018/02/19	**October-23**
19	INDIA	**MAXHEAL PHARMACEUTICALS (INDIA) LIMITED**	J-7, M.I.D.C., TARAPUR INDUSTRIAL AREA, BOISAR - 401506, MAHARAHSTRA, INDIA	ORAL CAPSULES, ORAL TABLETS, ORAL LIQUIDS, ORAL POWDERS, TOPICAL PREPARATIONS, DRY POWDERS	FDA/GMP/019/02/19	**October-23**
20	INDIA	**NAVKAR LIFESCIENCES PVT. LTD**	PLOT No. 76, LODHIMAJRA,INDUSTRIAL AREA,BADDI,DISTRICT-SOLAN (H.P)-173 205 , INDIA	ORAL TABLETS, ORAL CAPSULES,ORAL LIQUIDS, TOPICAL PREPARATIONS	FDA/GMP/020/02/19	**October-23**
21	INDIA	**PREMIUM SERUMS AND VACCINES PVT LIMITED, INDIA**	S. NO. 354-1 & 21/1, NARAYANGAON, TAL. JUNNAR PUNE, 410504 MAHARASHTRA STATE, INDIA	SMALL VOLUME PARENTERALS	FDA/GMP/021/02/19	**October-23**
22	INDIA	**SCOTT-EDIL PHARMACIA LTD**	56, E.P.I.P., PHASE-1, JHARMAJRI, BADDI, DISTT. SOLAN (H.P), -173 205, INDIA	ORAL TABLETS,ORAL CAPSULES, SMALL VOLUME PARENTERALS, TOPICAL PREPARATIONS	FDA/GMP/022/02/19	**October-23**
23	INDIA	**PANACEA BIOTECH LIMITED**	UNIT 1, PHARMA FORMULATIONS, MALPUR, BADDI, HIMACHAL PRADESH – 173 205, INDIA	ORAL TABLETS, ORAL CAPSULES (HARD AND SOFT), ORAL LIQUIDS	FDA/GMP/001/11/18	**November-23**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
24	INDIA	**AMANTA HEALTHCARE LIMITED**	876 N.H NO. 8 HARIYALA KHEDA 387411, GUJARAT, INDIA	SMALL AND LARGE VOLUME PARENTERALS	FDA/GMP/016/02/19	**November-23**
25	INDIA	**M/S BIOLOGICAL E. LTD**	BULK PRODUCT, 7-4-114 GAGANPAHAD , REJENDRA NAGAR MANDAL , RANGA REDDY (DISTRICT), TELANGANA, INDIA-500052	SMALL VOLUME PARENTERALS	FDA/GMP/023/02/19	**January-24**
26	USA	**ALEO VERA AMERICA INC.**	13745 JUPITER ROAD, DALLAS TEXAS 75238, U.S.A	ORAL LIQUIDS	FDA/GMP/015/01/19	**February-23**
27	INDIA	**BIOLOGICAL E. LTD**	BULK PRODUCT, 7-4-114 GAGANPAHAD, REJENDRA NAGAR MANDAL RANGA REDDY (DISTRICT), TELANGANA, , INDIA-500052	SMALL VOLUME PARENTERALS	FDA/GMP/023/02/19	**February-23**
28	INDIA	**M/S SUYAASH PHARMACEUTICALS**	216/5-6 VILLAGE, KHUNDH VANSDA ROAD, TAJ CHIKHLI DISTRICT, NAVSARI, GUJARAT, INDIA	SMALL VOLUME PARENTERALS	FDA/GMP/032/10/19	**May-23**
29	INDIA	**AKUMS DRUGS AND PHARMACEUTICAL LIMITED**	PLOT No 2, 3, 4 & 5 SECTOR-6B, PLOT No 19, 20, 21, 22, 47 & 48 SECTOR-6A, IIE SIDCUL, RANIPAR, HARIDWAR, UTTRAKHAND, INDIA	ORAL SOLIDS, ORAL LIQUIDS, SMALL VOLUME PARENTERALS , LARGE VOLUME PARENTERALS AND HORMONAL	FDA/GMP/027/04/19	**May-23**
30	INDIA	**MALLIK LIFESCIENCES PRIVATE LIMITED (FORMERLY AKUMS DRUGS AND PHARMACEUTICAL LIMITED)**	PLOT No. 16, VARDHMAN INDUSTRIAL ESTATE, VILLAGE-BAHADARPUR SAINI, N.H.-58, HARIDWAR, UTTARAKHAND, INDIA	CEPHALOSPORINS AND PENICILLINS	FDA/GMP/013/04/20	**May-23**
31	CHINA	**DESANO BIO-PHARMACEUTICALS LIMITED**	1479 ZHANHENG RD., SHANGHAI, CHINA	ORAL SOLIDS	FDA/GMP/028/04/19	**September-23**
32	INDIA	**BAXTER PHARMACEUTICALS INDIA PVT. LIMITED**	CHACHARWADI -VASAN, AHMEDABAD, GUJARAT 382213, INDIA	LARGE VOLUME PARENTERALS AND SMALL VOLUME PARENTERALS	FDA/GMP/030/05/19	**November-23**
33	PORTUGAL	**LABORATORIOS BASI-INDUSTRIA FARMACEUTICA-SA**	PARQUE INDUSTRIAL MANUEL LOURENCO FERREIRA, LOTE 15, 232MORT 3450-232 MORTUGUA, PORTUGAL	ORAL LIQUIDS, SEMI SOLIDS, TOPICAL PRAPARATIONS	FDA/GMP/026/04/19	**February-24**
34	INDIA	**OTSUKA PHARMACEUTICAL INDIA PVT LIMITED**	SURVEY NO. 199 to 201, 208 to 210, VILLAGE-VASANA, TULAKU-SANAND, AHMEDABAD - 382213 INDIA	LARGE VOLUME PARENTERALS AND SMALL VOLUME PARENTERALS	FDA/GMP/029/05/19	**October-23**
35	CHINA	**REYOUNG PHARMACEUTICALS COMPANY LIMITED**	NO. 1 REYANG ROAD, YIYANG COUNTY, SHANDONG PROVINCE P.R. CHINA	ORAL SOLIDS, POWDER INJECTIONS, SEMI-SOLIDS	FDA/GMP/024/04/19	**September-23**
36	MALTA	**SIEGFRIED MALTA LIMITED**	HHF070 HAL FAR INDUSTRIAL ESTATE, HAL FAR BBG3000, MALTA	ORAL SOLIDS	FDA/GMP/025/04/19	**January-24**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
37	INDIA	**MSN LABORATORIRES PRIVATE LIMITED**	PLOT NO. 42 ANRICH INDUSTRIAL ESTATE, BOLARAM SANGARAREDDY DISTRICT - 502 325, TELANGAN INDIA	ORAL SOLIDS, SMALL VOLUME PARENTERALS	FDA/GMP/031/10/19	**January-24**
38	INDIA	**AJANTA PHARMA LIMITED**	PAITHAN MANUFACTURING UNIT, B - 4/5/6, MIDC INDUSTRIAL AREA, PAITHAN 431 148, AURANGABAD DISTRICT, MAHARASHTRA, INDIA	ORAL TABLETS, ORAL CAPSULES, ORAL POWDERS	FDA/GMP/015/08/20	**November-24**
39	INDIA	**BLISS GVS PHARMA LIMITED**	PLOT NO. 10, 11 & 12, SURVEY NO. 38/1, DEWAN UDYOG NAGAR, ALIYALI, PALGHAR, MAHARASHTRA 401404, INDIA	ORAL TABLES, ORAL LIQUIDS, SUPPOSITORIES, PESSARIES	FDA/GMP/003/02/20	**November-24**
40	INDIA	**CHARAK PHARMA PRIVATE LIMITED**	JAURASI ROAD, PAUTI VILLAGE, SAMALKHA, DIST PANIPAT-132 101 HARYANA, INDIA	ORAL SOLIDS	FDA/GMP/014/08/20	**November-24**
41	INDIA	**CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED**	PLOT NO. 35 TO 37, 43 TO 45 CFC-B, DEWAN UDYOG NAGAR ALIYALI VILLAGE, PALGHAR MAHARASTHRA, INDIA	ORAL TABLETS, ORAL CAPSULES, ORAL LIQUIDS, DRY SYRUPS, EXTERNAL PREPARATION	FDA/GMP/009/03/20	**November-24**
42	INDIA	**CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED**	PLOT NO. 118, 119, 113, 118/1, 119/1, 119/2, MIDC TARAPUR, BOISAR, PALGHAR DISTRICT - 401506 MAHARASTHRA, INDIA	ORAL LIQUIDS, OPTHALMIC PREPARATIONS, POWDER FOR INJECTION, PRE-FILLED SYRINGES, SMALL VOLUME PARENTERALS, LYOPHILIZED PARENTERALS/BULK	FDA/GMP/010/03/20	**November-24**
43	GERMANY	**DENK PHARMA GmbH**	GOELLSTRASSE 1, 84529 TITTMONING, GERMANY	ORAL TABLETS, ORAL LIQUIDS	FDA/GMP/006/03/20	**November-24**
44	INDIA	**INDASI LIFESCIENCE PRIVATE LIMITED**	PLOT NO. 73-76, SILVER INDUSTRIAL ESTATE, BHIMPORE, DAMAN, INDIA	SMALL VOLUME PARENTERALS	FDA/GMP/005/02/20	**November-24**
45	INDIA	**INDIANA OPTHALMICS**	135, 136, 137 PHASE-II, G.I.D.C ESTATE, WADHWAN CITY, SURENDRANAGAR DISTRICT – 363035, GUJARAT, INDIA	OPTHALMIC PREPARATIONS	FDA/GMP/020/09/20	**November-24**
46	INDIA	**KHANDELWAL LABORATORIES PRIVATE LIMITED**	PLOT NO. 20, SECTOR 6, IIE SIDCUL, PANTNAGAR, DIST. UDHAM SINGH NAGAR PIN-263153, UTTARAKHAND, INDIA	ORAL TABLETS, CEPHALOSPORIN	FDA/GMP/002/02/20	**November-24**
47	INDIA	**KREMOINT PHARMA LIMITED**	B-8, ADDITIONAL AMBERNATH MIDC, OPPOSITE ANAND NAGAR POLICE CHECK POST, AMBERNATH (E), DIST: THANE 421506, MAHARASHTRA, INDIA	TOPICAL PREPARATIONS	FDA/GMP/004/02/20	**November-24**
48	PUERTO RICO	**MSD INTERNATIONAL GmbH LLC**	PRIDCO INDUSTRIAL PARK, STATE ROAD 183, LAS PIEDRAS, PUERTO RICO	ORAL TABLETS, ORAL CAPSULES	FDA/GMP/013/08/20	**November-24**
49	INDIA	**NAARI PHARMA PRIVATED LIMITED**	PLOT NUMBER 14-15, & 55-57, SECTOR 5, IIE, PANTNAGAR, RUDRAPUR-263153, DIST. UDHAM SINGH NAGAR, UTTARAKHAND, INDIA.	ORAL TABLETS	FDA/GMP/001/02/20	**November-24**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
50	INDIA	**SAKAR HEALTHCARE LIMITED**	BLOCK NO. 10 - 13 SARKHEJ - BAVLA HIGHWAY VILLAGE – CHANGODAR AHMEDABAD - 38221, GUJARAT, INDIA	ORAL LIQUIDS, CEPHALOSPORINS, SMALL VOLUME PARENTERALS, LARGE VOLUME PARENTERALS	FDA/GMP/011/03/20	**November-24**
51	INDIA	**SERUM INSTITUTE OF INDIA PRIVATE LIMITED**	212/2, HADAPSAR, PUNE -28, PUNE 411028, INDIA	BIO-THERAPEUTICS, VACCINES	FDA/GMP/021/11/20	**November-24**
52	INDIA	**TIL HEALTHCARE PRIVATE LIMITED**	PLOT NO: 100 WEST, R5 SOUTH, SRICITY SEZ, CHERIVI VILLAGE, IRUGULAM POST, SATYAVEDU MANDAL, CHITTOOR DISTRICT – 517588 ANDHRA PRADESH, INDIA.	DRYPOWDERS (ORAL SUSPENSION), ORAL LIQUIDS, ORAL CAPSULES, ORAL TABLETS	FDA/GMP/019/09/20	**November-24**
53	INDIA	**MYLAN LABORATORIES LIMITED**	SY. NO. S 16 AND S 17 GREEN INDUSTRIAL PARK POLEPALLY VILLAGE, JADCHERLA MANDAL, DIST. MEHBOOBNAGAR, TELANGANA STATE 509202. INDIA	ORAL SOLIDS	FDA/GMP/016/08/20	**November-24**
54	INDIA	**UNICHEM LABORATORIES LIMITED**	BADDI UNIT-11 LOCATED AT BADDI; VILLAGE BHATAULI KALAN, BADDI-173205, DISTRICT SOLAN (H.P.) INDIA	SOLID DOSAGE FORMS	FDA/GMP/012/03/20	**November-24**
55	INDIA	**BHARAT BIOTECH INTERNATIONAL LIMITED**	GENOME VALLEY, SHAMEERPET, MANDAL HYDERABAD MEDCHAL DISTRICT 500 078, TELENGANA STATE	BIO-THERAPEUTICS, VACCINES	FDA/GMP/001/02/21	**November-24**
56	TURKEY	**NOVARTIS SAGLIK GIDA TARIM URUNLERI SAN VE TIC. A.S.**	YENISEHIR MAHALLESI IHLARA VADISI SOKAK, NO. 2 34912, PENDIK, ISTANBUL, TURKEY	ORAL TABLETS, ORAL CAPSULES, LOZENGES	FDA/GMP/007/03/20	**November-24**
57	TURKEY	**SANDOZ ILAC SANAYI VE TIC. A.S.**	GEBZE PLASTIKCILER ORGANIZE SANAYI BOLGESI INONII MAH. ATATURK BULVARI 9. CADDE NO. 41400 KOCAELI, TURKEY	ORAL TABLETS, ORAL LIQUIDS, SUPPOSITORIES, EXTERNAL PREPARATIONS	FDA/GMP/008/03/20	**November-24**
58	UNITED KINGDOM	**GLAXO OPERATIONS UK LIMITED**	HARMIRE ROAD, BARNARD CASTLE, COUNTY DURHAM, DL 12 8DT, UNITED KINGDOM	ORAL SOLIDS, TOPICAL PREPARATIONS, CEPHALOSPORINS, STERILE PRODUCTS, SMALL VOLUME PARENTERALS, LARGE VOLUME PARENTERALS	FDA/GMP/018/08/20	**August-25**
59	UNITED KINGDOM	**SMITHKLINE BEECHAM PHARMACEUTICALS LIMITED**	CLARENDON ROAD, WORTHING, WEST SUSSEX, BN14 8QH, UNITED KINGDOM	DRY POWDERS (ORAL SUSPENSION), TOPICAL PREPARATIONS, ORAL LIQUIDS, ORAL SOLIDS, STERILE PRODUCTS, INJECTABLES	FDA/GMP/017/08/20	**August-25**

EXPIRED LICENSES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE		VALID UNTIL
1	BANGLADESH	**BEACON PHARMACEUTICALS LIMITED**	153-154 TESGAON I/A DHAKA - 1208 BHALUKA, MYMEMSINGH BANGLADESH.	ORAL SOLIDS (TABLETS, CAPSULES, DRY POWDERS FOR SUSP.), SMALL VOLUME PARENTERALS, LYOPHILIZED INJECTABLES	FDA/GMP/003/02/15	**October-19**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
2	BANGLADESH	**HEALTHCARE PHARMACEUTICAL LIMITED**	WAGE EARNERS COMPLEX, 71-72 OLD ELEPHANT GARDEN, DHAKA - 1000 BANGLADESH	ORAL SOLIDS AND SEMI-SOLIDS, STERILE PRODUCTS (METERED DOSE SELLERS)	FDA/GMP/001/02/15	**OCT19**
3	INDIA	**AUROCHEM LABORATORIES (1) PVT. LTD**	PLOT NO. 8, PALGHAR TALUKA IND. CO-OP ESTATE LTD. BOISAR ROAD, PALGHAR - 401 404, INDIA	CREAMS, OINTMENT, LIQUIDS	FDA/GMP/016/02/15	**November-19**
4	CHINA	**GUILIN PHARMACEUTICALS COMPANY LTD**	NO. 43, QILIDIAN ROAD, GUILIN, GUANGXI, CHINA, 541004	ORAL SOLIDS (TABLETS, HARD AND SOFT GELATINE CAPSULES), LARGE AND SMALL VOLUME PARENTERALS, STERILE APIs	FDA/GMP/010/02/15	**November-19**
5	SOUTH AFRICA	**JOHNSON & JOHNSON (PTY) LTD**	241 MAIN ROAD, RETREAT, CAPE TOWN, 7945	ORAL LIQUIDS (SYRUPS)	FDA/GMP/019/02/15	**November-19**
6	INDIA	**AXA PARENTERALS LTD**	PLOT NO. 936, 937, 939 KISHANPUR, JAMALPUR, ROORKE DIST.: HARIDWAR 247667, UTTARAKHAND, INDIA	LARGE AND SMALL VOLUME OPHTHALMIC PREPARATIONS	FDA/GMP/017/02/15	**November-19**
7	INDIA	**AHLCON PARENTERALS PVT. LIMITED**	SP-917 & 918, PHASE - III,RIICO INDUSTRIAL AREA, BHIWADI 301 019 DIST. ALWAR (RAJASTHAN), INDIA	LARGE AND SMALL VOLUME PARENTERALS, STERILE OPHTHALMIC DROPS	FDA/GMP/024/02/15	**December-19**
8	INDIA	**AKRITI PHARMACEUTICALS PVT. LTD**	PLOT NO. D-10 & D-11, M.I.D.C. INDUSTRIAL ESTATE, JEJURI, TALUKA - PURANDHAR (SASWAD), DIST. PUNE – 412 303 MAHARASHTRA, INDIA	ORAL SOLIDS (TABLETS, HARD GELATINE CAPSULES, DRY POWDER FOR SUSP.), TOPICAL PREPARATIONS (CREAMS AND LOTIONS), POWDER FOR INJECTION.	FDA/GMP/014/02/15	**December-19**
9	INDIA	**CIPLA LIMITED**	PLOT NO. A-33, A-2 (UNIT -1), A-42 (UNIT-II), MIDC PATALGANGA, 410220, DISTRICT RAIGAD, MAHARASHTRA INDIA	ORAL SOLIDS (TABLETS), TOPICAL PREPARATIONS, NASAL DROPS	FDA/GMP/004/02/15	**December-19**
10	NIGERIA	**JUHEL NIGERIA LIMITED**	PLOT PD/5, EXECUTIVE LAYOUT, AWKA, ANAMBRA STATE, NIGERIA	SMALL AND LARGE VOLUME PARENTERALS, OPHTHALMIC SOLUTION	FDA/GMP/023/02/15	**December-19**
11	INDIA	**M/S SOFTGEL HEATHCARE PVT LTD**	NO. 20/1, VANDALUR-KELLAMBAKAM ROAD, VILLAGE-PUDUPAKKAM. DIST. KANCHIPOORAM. TAMIL NADU, INDIA	SOFT GELATINE CAPSULES	FDA/GMP/006/02/15	**December-19**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
12	INDIA	**MICROLABS LIMITED**	121-124, IV PHASE KIADB, BOMMASANDRA, JIGINI LINK ROAD. ANEKAL TALUK, BANGALORE 560099 INDIA	ORAL SOLIDS (TABLETS, CAPSULES AND DRY POWDER FOR SUSP.), STERILE DRY POWDER FOR INJECTION	FDA/GMP/015/02/15	**December-19**
13	INDIA	**STERIL-GENE LIFE SCIENCES (P) LTD**	NO. 45, MAIN ROAD, MANGALAM VILLAGE, VILLIANUR COMMUNE, PUDUCHERRY-605110, INDIA	ORAL SOLIDS (TABLETS, CAPSULES AND SUSPENSIONS), INJECTABLE (DRY POWDER FOR INJECTIONS)	FDA/GMP/005/02/15	**December-19**
14	INDIA	**THE MADRAS PHARMACEUTICALS**	137-B, OLD MAHABALIPURAM ROAD, KARAPAKKAM, CHENNAI-600 096, INDIA	ORAL SOLIDS (TABLETS, CPASULES AND DRY POWDER FOR SUSP), ORAL LIQUIDS, TOPICAL PREPARATIONS (OINTMENTS)	FDA/GMP/007/02/15	**December-19**
15	INDIA	**SANCE LABORATORIES PRIVATE LIMITED**	VI/51, P.B.No.2, KOZHUVANAL-686573 PALA, KOTTAYAM DIST., KERALA, INDIA	ORAL SOLIDS (TABLETS, CAPSULES AND SUSPENSIONS), DRY POWDER FOR INJECTIONS	FDA/GMP/013/01/16	**April-20**
16	INDIA	**SHALINA LABORATORIES PVT LTD.**	E-2 MIDC, TALUKA-PWANDAL, PUNE, MAHARASHTRA	EXTERNAL PREPARATIONS, ORAL SOLIDS	FDA/GMP/003/01/16	**April-20**
17	INDIA	**STRIDES SHASUN LTD (STRIDES ARCOLAB I)**	KRS GARDENS, SURAGAJAKKANAHALLI, INDLAVADI CROSS, ANEKAL TALUK, BANGALORE SOUTH - 562106	ORAL SOLIDS, SMALL AND LARGE VOLUME PARENTERALS	FDA/GMP/004/01/16	**April-20**
18	INDIA	**IPCA LABORATORIES LIMITED**	DEHRADUN UNIT II G6, SARA INDUSTRIAL AREA, CHAKRATA ROAD, RAMPUR DEHRADUN, 248197 UTTARAKHAND, INDIA	ORAL SOLIDS-BETA LACTAMS (TABLETS, DRY POWDERS), DRY POWDER, INJECTABLES (CEPHALOSPORINS)	FDA/GMP/019/01/16	**April-20**
19	INDIA	**IPCA LABORATORIES LIMITED**	SECTOR-II, PLOT NO. 69-72(13) KANDLA SPECIAL ECONOMIC ZONE (KSEZ), GANDHIDHAM, GUJRAT, INDIA	>ORAL SOLIDS-BETA LACTAMS (TABLERTS, CAPSULES AND DRY POWDER FOR SUSP.)	FDA/GMP/020/01/16	**April-20**
20	INDIA	**NAVKETAN PHARMA PVT LIMITED**	F-106, MIDC, WALUJ, AURANGABAD-431136, M.S, INDIA	ORAL LIQUIDS, ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/007/01/16	**April-20**
21	INDIA	**NAVKETAN RESEARCH & LAB PVT LIMITED**	F-107,108 MIDC WALUJ, AURANGABAD M.S	POVIDONE-IODINE, TOPICAL PREPATIONS (OINTMENT, POWDERS, LOTIONS, IODINE SOLUTION)	FDA/GMP/008/01/16	**April-20**
22	INDIA	**MEYER ORGANICS**	#10-D, 2ND PHASE PEENYA INDUSTRIAL AREA, BANGALORE 560058, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS	FDA/GMP/023/01/16	**May-20**
23	INDIA	**ORCHID HEALTHCARE**	PLOT NO.. B-77, SIDCO INDUSTRIAL ESTATE, ALATHUR, KANCHEEPURAM DIST., TAMIL NADU 603110, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS	FDA/GMP/024/01/16	**May-20**
24	INDIA	**ACME FORMULATIONS PVT LTD**	ROPAR ROAD, NALAGARH DISTRICT, BADDI, HIMANCHAL PRADESH 174101, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES)	FDA/GMP/016/01/16	**June-20**

7 of 13

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
25	EGYPT	**AMRIYA PHARMACEUTICAL INDUSTRIES**	KILOMETER 25, ALEXANDRIA-CAIRO, DESERT ROAD, AMRIYA, ALEXANDRIA-EGYPT	ORAL SOLIDS (DRY POWDER FOR SUSP.), ORAL LIQUIDS, SMALL VOLUME, PARENTERALS, TOPICAL PREPARATIONS	FDA/GMP/026/01/16	**June-20**
26	INDIA	**GOPALDAS VISRAM & CO. LTD.**	PLOT NO. A590/591 TTC INDUSTRIAL AREA, M.I.D.C. MAHAPE, NAVI MUMBAI 400701, INDIA	ORAL LIQUIDS, TOPICAL PREPARATIONS	FDA/GMP/017/01/16	**June-20**
27	INDIA	**GUJARAT LIQUI PHARMACAP PVT LIMITED**	PLOT NO.662-666, GIDC WAGHODIA, VADODARA-391760, GUJARAT, INDIA	ORAL CAPSULES	FDA/GMP/001/01/16	**June-20**
28	INDIA	**INVENTIA HEALTHCARE PRIVATE LIMITED**	F1-F1/1 ADDITIONAL AMBERNATH MIDC, AMBERNATH (E) DIST., THANE 421506, MAHARASHTRA INDIA	ORAL TABLETS, ORAL CAPSULES, PELLETS AND GRANULES	FDA/GMP/018/01/16	**June-20**
29	INDIA	**IPCA LABORATORIES LIMITED**	P.O SEJAVTA DIST., RATLAM-457002 (MP)	ORAL SOLIDS (TABLETS, DRY POWDER FOR SUSP.), ORAL LIQUIDS, INJECTABLES (DRY POWDERS, LIQUIDS)	FDA/GMP/021/01/16	**June-20**
30	INDIA	**IPCA LABORATORIES LIMITED**	PLOT NO. 255/1, VILLAGE ATHAL. DADRA & NAGAR HAVELI UNION TERRRITORY, SILVASSA 396230, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES)	FDA/GMP/022/01/16	**June-20**
31	INDIA	**MVC PHARMACEUTICALS (C/O DUPEN LABORATORIES PVT LTD)**	C1-49 &36, DEGAM ROAD, INDUSTRIAL TOWNSHIP, GIDC VAPI-396195, GUJARAT, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS, EXTERNAL PREPARATIONS	FDA/GMP/009/01/16	**June-20**
32	INDIA	**UMEDICA LABORATORIES PVT. LTD**	PLOT NO. 221 GIDC, 2ND PHASE VAPI-396 195,GUJARAT, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES AND DRY POWDERS FOR SUSP.), SMALL VOLUME PARENTERALS	FDA/GMP/005/01/16	**June-20**
33	INDIA	**UNICHEM LABORATORIES LTD.**	C-31 & 32 INDUSTRIAL AREA, MEERUT ROAD, GHAZIABAD–201 003 UTTAR PRADESH.	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS (SYRUPS AND SUSPENSIONS), SMALL VOLUME INJECTABLE (AMPOULES).	FDA/GMP/006/01/16	**June-20**
34	INDIA	**MYLAN LABORATORIES LIMITED (MATRIX LABORATORIES LIMITED)**	F-4 & F-12, MIDC, MALEGAON SINNAR NASHIK-422113, MAHARASHTRA	ORAL SOLIDS (TABLETS AND CAPSULES)	FDA/GMP/002/01/16	**June-20**
35	INDIA	**BHARAT PARENTERALS LIMITED**	SURVEY NO. 144 &146, VILLAGE HARIPURA, TALUKA SAVLI, JAROP SAMLAYA ROAD, DIST-VADODARA, GUJARAT-391520, INDIA	ORAL SOLIDS, ORAL LIQUIDS, SMALL VOLUME PARENTERALS, (STERILE POWDER FOR INJECTIONS), TOPICAL PREPARATIONS (STERILE OINTMENT)	FDA/GMP/028/01/16	**October-20**
36	INDIA	**LINCOLN PHARMACEUTICAL LIMITED**	10, 12, 13, TRIMUL ESTATE, KALOL, GHANDHINAGAR, GUJARAT STATE, INDIA	ORAL SOLIDS, ORAL LIQUIDS, SMALL VOLUME PARENTERALS (STERILE POWDER), TOPICAL PREPARATIONS (STERILE OINTMENT)	FDA/GMP/030/01/16	**October-20**
37	INDIA	**MANEESH EXPORTS (EOU)**	PLOT No.D-16/7, T.T.C. INDUSTRIAL AREA, M.I.D.C., TURBHE, NAVI MUMBAI-400703	ORAL SOLIDS-BETA LACTAMS (TABLETS AND CAPSULES), STERILE POWDERS FOR INJECTION-BETA LACTAM)	FDA/GMP/027/01/16	**October-20**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
38	INDIA	**MEDREICH LIMITED (UNIT 2)**	NO 49B BOMAMASANDRA INDUSTRIAL AREA, ANEKAL TALUK, BANGALORE, 560-099, INDIA.	HARD GELATIN CAPSULES	FDA/GMP/010/01/16	**October-20**
39	INDIA	**MEDREICH LIMITED (UNIT 7)**	UNIT 7, SURVEY NO. 11, 12, 13 & 15, POOJARAMANAHALLI VILLAGE, HOSKOTE TALUK, BANGALORE RURAL DISTRICT - 562114, INDIA.	ORAL SOLID (TABLETS AND CAPSULES)	FDA/GMP/011/01/16	**October-20**
40	INDIA	**RATNAMANI HEALTHCARE PVT LIMITED**	SURVEY NO. 750/1, AHMEDABAD-MEHSANA HIGHWAY, VILLAGE-INDRAD, TAL. KADHI, DIST. MEHSANA, GUJARAT, INDIA - 382721	ORAL SOLIDS-BETA LACTAMS (TABLETS, CAPSULES AND DRY POWDER FOR SUSP.), ORAL LIQUIDS ORAL SOLIDS.	FDA/GMP/029/01/16	**October-20**
41	INDIA	**SWISS PARENTERALS PVT LIMITED**	809, KERALA INDUSTRIAL ESTATE, NR BAVLA, AHMEDABAD, GIDC, GUJARAT STATE, INDIA.	STERILE DRY POWDERS FOR INJECTION, SMALL VOLUME PARENTERALS	FDA/GMP/012/01/16	**October-20**
42	INDIA	**ASTAMED HEALTHCARE (I) PVT LTD**	PLOT No. 2 & 3 PHASE II, GENESIS INDUSTRIAL COMPLEX, KOLGAON, TAL: PALGHAR, DIST.: THANE, MAHARASHTRA-INDIA	ORAL SOLIDS (TABLETS, CAPSULES AND DRY POWDER FOR SUSP.), ORAL LIQUIDS, TOPICALS, DRY POWDER FOR SUSPENSION.	FDA/GMP/015/01/16	**November-20**
43	INDIA	**BAADER SCHULZ LABORATORIES PHARMA DIVISION**	PLOT No.: J-6 OIDC, M.G. UDYOG NAGAR, DABHEL, NANI DAMAN, PIN: 396210 INDIA	ORAL SOLIDS (TABLETS, CAPSULES, POWDER-ORS), ORAL LIQUIDS, OINTMENT	FDA/GMP/014/01/16	**November-20**
44	INDIA	**ENICAR PHARMA**	PLOT NO. J/214,215 M.I.D.C TARAPUR INDUSTRIAL AREA, THANE MAHARASHTRA	ORAL LIQUIDS	FDA/GMP/002/05/16	**March-21**
45	INDIA	**MEDIBIOS LABORATORIES PVT LIMITED**	PLOT NO. J-76, M.I.D.C. TARAPUR, BOISAR, THANE-401506	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.)	FDA/GMP/001/05/16	**March-21**
46	INDIA	**ACULIFE HEALTHCARE PVT LTD**	UNITS 2,5,6,7&8 VILLAGE-SACHANA, TALUKA-VIRAMGAM, AHMEDABAD 382150, GUJARAT	LARGE AND SMALL VOLUME PARENTERALS-BETA LACTAMS (STERILE DRY POWDER FOR INJECTION), ORAL SOLIDS-BETA AND NON-BETA LACTAMS (TABLETS, CAPSULES, DRYPOWDER FOR SUSP.), OPHTHALMIC EAR AND NASAL SOLUTIONS, TOPICAL PREPARATIONS, ORAL LIQUIDS.	FDA/GMP/002/10/16	**April-21**
47	INDIA	**ADCOCK INGRAM LIMITED**	NO. 49 C & D BOMMASANDRA INDUSTRIAL AREA, ANEKAL TALUK, BANGALORE -560 099, INDIA	ORAL SOLIDS (TABLETS, CAPSULES, PELLETS)	FDA/GMP/001/10/16	**April-21**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
48	INDIA	**AISHWARYA LIFESCIENCES**	PLOT NUMBER: 11, INDUSTRIAL AREA, VILLAGE- LODHIMAJRA POST: MANPURA TEHSIL: NALAGARH DISTT- SOLAN HIMACHAL PRADESH - 174101 INDIA	LARGE & SMALL VOLUME PARENTERALS, INJECTABLES	FDA/GMP/005/10/16	**April-21**
49	INDIA	**EMCURE PHARMACEUTICALS LTD**	IT BT PARK, PHASE II, HINJAWADI, PUNE, 411057, MAHARASHTRA INDIA	ORAL SOLIDS (TABLETS), SMALL VOLUME, INJECTABLES, STERILE ONCOLOGY PARENTERALS	FDA/GMP/003/05/16	**April-21**
50	INDIA	**M/S SAMRUDH PHARMACEUTICALS PVT LTD**	J-174, J-168 & J-168/1, M.I.D.C., TARAPUR, BOISAR, DIST. THANE 401 506, INDIA	DRY POWDER FOR INJECTION (CEPHALOSPORINS)	FDA/GMP/005/05/16	**April-21**
51	INDIA	**MERCURY LABORATORIES LIMITED**	UNIT NO. 2,MLL-II, HALOL-BARODA ROAD, NR. JAROD, VADODARA, GUJARAT, INDIA	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.), ORAL LIQUIDS	FDA/GMP/003/10/16	**April-21**
52	INDIA	**OXALIS LABS**	VILLAGE THEDA, P.O. LODHIMAJRA, BADDI DIST. SOLAN, HIMACHAL PRADESH	ORAL SOLIDS (TABLETS, SOFT GELATTINE, CAPSULES, POWDERS FOR SUSP.), TOPICAL PREPARATIONS, INHALERS (MDI)	FDA/GMP/004/10/16	**April-21**
53	INDIA	**VERVE HUMAN CARE LABORATORIES**	PLOT NO.: 15A, PHARMACITY SELAQUI–DEHRADUN UTTARAKHAND, INDIA	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.)	FDA/GMP/004/05/16	**April-21**
54	UGANDA	**CIPLA QUALITY CHEMICAL INDUSTRIES LIMITED**	PLOT NO.: 1-7, 1ST RING ROAD, LUZIRA INDUSTRIAL PARK	ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/001/06/16	**June-21**
55	INDIA	**INJECTCARE PARENTERALS PVT LTD**	PLOT NO. 130 SILVASSA ROAD, G.I.D.C, VAPI-396 195, GUJARAT, INDIA	POWDER FOR INJECTION-BETA LACTAMS	FDA/GMP/005/01/17	**October-21**
56	INDIA	**INTAS PHARMACEUTICALS LTD**	CAMP ROAD, SELAQUI-DEHRADUN, UTTARAKHAND, INDIA	ORAL SOLIDS (TABLETS, HARD GELATINE CAPSULES)	FDA/GMP/009/01/17	**October-21**
57	INDIA	**MAXHEAL LABORATORIES PVT LTD**	PLOT NO. 2-7/80-85, SURSEZ, SACHIN, SURAT-394 230	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.)	FDA/GMP/001/01/17	**October-21**
58	INDIA	**PROWILL PHARMACEUTICALS PVT. LTD**	D 28/16, TTC INDUSTRIAL AREA, MIDC, TURBHE, NAVI MUMBAI-400705, MAHARASHTRA, INDIA	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.)	FDA/GMP/008/01/17	**October-21**
59	INDIA	**SAI MIRRA INNOPHARMA PVT LTD**	PLOT NO. 288 & 289 SIDCO ESTATES, AMBATTUR, CHENNAI-600 098, TAMIL NADU, INDIA	ORAL SOLIDS (TABLETS, CAPSULES,DRY POWDERS FOR SUSP.), ORAL LIQUIDS	FDA/GMP/002/01/17	**October-21**
60	INDIA	**PULSE PHARMACEUTICALS PVT LTD**	KHASRA NO. 409, KARONDI ROORKEE, DIST OF HARIDWAR, UTTARAKHAND, INDIA	ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/010/01/17	**October-21**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
61	INDIA	**BIOCON LIMITED**	SPECIAL ECONOMIC ZONE PLOT NO. 2-4, PHASE IV, BOMMANSANDRA JIGANI LINK ROAD, BOMMANSANDRA POST, BANGALORE-560099, INDIA	INSULIN INJECTION AND ITS VARIANTS, TRASTUZUMAB INJECTIONS	FDA/GMP/003/01/17	**October-21**
62	INDIA	**STP PHARMACEUTICALS PVT LIMITED**	SANGKHOLA,SINGTAM. EAST SIKKIM-737134	ORAL LIQUIDS, OINTMENTS, CREAMS AND GELS	FDA/GMP/004/01/17	**October-21**
63	INDIA	**CADILA PHARMACEUTICALS LIMITED**	SURVEY NO. 1389. TRASAD ROAD DHOLKA 38222. DIST- AHMEDABAB.	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS DRY POWDER INJECTABLES (BETA-LACTAMS), SMALL VOLUME PARENTERALS(BETA LACTAMS), HERBAL MEDICINES (TABLETS AND CAPSULES), ORAL LIQUIDS, TOPICALS	FDA/GMP/006/01/17	**October-21**
64	BANGLADESH	**ARISTOPHARMA LIMITED**	PLOT # 16, 17, 19,20,21 & 22, ROAD # 11 & 12 SHAMPUR-KADAMTALI, INDUSTRIAL AREA, DHAKA-1204, BANGLADESH	ORAL SOLIDS, ORAL LIQUIDS, STERILE DOSAGE FORMS, TOPICAL PREPARATIONS, SUPPOSITORIES, METERED DOSE INHALERS	FDA/GMP/001/03/17	**October-21**
65	INDIA	**AUROBINDO PHARMA LIMITED**	SEZ –APIIC UNIT - VII SURVEY NUMBER 411,425, 434, 435 AND 458, GREEN INDUSTRIAL PARK, POLEPALLY (VILLAGE), JADCHERIA (MANDAL), MAHABOOBNAGAR DISTRICT, ANDHRA PRADESH, INDIA	ORAL SOLIDS (TABLETS AND CAPSULES	FDA/GMP/004/01/17	**November-21**
66	INDIA	**SHANTHA BIOTECHNICS PRIVATE LTD (A SANOFI COMPANY)**	SURVEY NO. 274, ATHVELLI VILLAGE MEDCHAL MANDAL-501401, RANGA REDDY (DIST), TELANGANA INDIA	RECOMBINANT VACCINES, BACTERIAL VACCINES	FDA/GMP/002/05/17	**November-21**
67	INDIA	**ZEISS PHARMACEUTICALS LIMITED**	72, EXPORT PROMOTION INDUSTRIAL PARK, PHASE-I, JHARMAJRI, BADDI (H.P) – 173 205, INDIA	CEPHALOSPORIN, DRY POWDER FOR INJECTION (BETA-LACTAM)	FDA/GMP/003/05/17	**January-22**
68	GERMANY	**HAMELM PHARMACEUTICAL GMBH,**	LANGES FELD 13 HAMELM GERMANY	SMALL AND LARGE VOLUME PARENTERALS	FDA/GMP/001/11/17	**January-22**
69	GERMANY	**TAKEDA GMBH**	ORANIENBURG, LEHNITZSTR.70-98, 16515 ORANIENBURG, GERMANY	ORAL SOLIDS (TABLETS, CAPSULES, PELLETS, GRANULES)	FDA/GMP/002/11/17	**January-22**
70	INDIA	**TRIDENT LIFELINE LTD C/O MARS REMEDIES PVT LIMITED**	635 GIDC ESTATE, WAGHODIA 391 760, VADODARA, GUJARAT - INDIA	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS, TOPICAL PREPARATIONS (BETA AND NON-BETA LACTAMS)	FDA/GMP/001/06/17	**March-22**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
71	INDIA	**CENTURION LABORATORIES PVT LIMITED**	P-2, BIOTECH PARK, MANJUSAR, SAVLI, BARODA, GUJARAT - INDIA	ORAL SOLIDS (TABLETS AND CAPSULES), ORAL LIQUIDS	FDA/GMP/002/06/17	**March-22**
72	INDIA	**SOCOMED PHARMA PVT LTD C/O IMPULSE PHARMA PVT LIMITED**	J 201, J 202/1, MIDC, TARAPUR, BOISAR, DIST-PALGHAR – 401 506 INDIA	ORAL SOLIDS (TABLETS AND CAPSULES)	FDA/GMP/003/06/17	**March-22**
73	INDIA	**SYNOKEM PHARMACEUTICAL LIMITED**	PLOT 35-36, SECTOR-6A, I.I.E (SIDCUL) RANIPUR (BHELL),HARIDWAR – 249 403	ORAL SOLIDS (TABLETS AND CAPSULES, SUSPENSIONS AND SYRUPS), HORMONES (TABLETS AND CAPSULES)	FDA/GMP/004/06/17	**March-22**
74	INDIA	**IMPACT HEALTCARE PVT LTD C/O MEDICEF PHARMA LIMITED**	PLOT No-28 EPIP PHASE-I JHARMAJRI, BADDI DIST: SOLAN (H.P) - INDIA	ORAL SOLIDS-BETA LACTAMS (TABLETS, DRY POWDER FOR SUSP.)	FDA/GMP/005/06/17	**March-22**
75	INDIA	**UNICHEM LABORATORIES LIMITED**	VILLAGE BHATAULI KALAN, BADDI – 173205 DIST: SOLAN (H.P), INDIA	DRY POWDER INJECTIONS, ORAL SOLIDS-BETA LACTAMS (TABLETS, DRY POWDER FOR SUSP.)	FDA/GMP/006/06/17	**April-22**
76	INDIA	**SPARSH BIO-TECH PVT LIMITED**	PLOT No. 1 SURVEY No.242/243/244, VILLAGE LAKHABAVAD,POST KHODIYAR COLONY, DIST. JAMNAGAR – 361006, GUJARAT INDIA	ORAL SOLIDS-BETA LACTAMS (TABLETS, DRY POWDER FOR SUSPENSION)	FDA/GMP/007/06/17	**April-22**
77	INDIA	**M/S GLOBELA PHARMA PVT LIMITED**	357, G.I.D.C, SACHIN, SURAT – 394230, GUJARAT INDIA	ORAL DRY POWDERS, CYTOTOXIC (TABLETS, CAPSULES), ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/008/06/17	**April-22**
78	INDIA	**MYLAN LABORATORIES LIMITED**	PLOT No. 11,12 & 13 INDORE SPECIAL ECONOMIC ZONE, PHARMA ZONE PHASE II SECTOR-III PITHAMPUR, DIST. DHAR (M.P) 454775 INDIA	ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/009/06/17	**April-22**
79	SOUTH AFRICA	**MERCK (PTY) LTD C/O NKUNZI PHARMACEUTICALS (PTY) LIMITED**	CIVITAS BUILDING 42, THABO SAHUME STREET, PRETORIA 0001	ORAL LIQUIDS, SEMI SOLIDS, ORAL SOLIDS (TABLETS AND CAPSULES)	FDA/GMP/010/06/17	**April-22**
80	SOUTH AFRICA	**ADCOCK INGRAM LIMITED**	1 NEW ROAD, ERAND GARDENS, MIDRAND, JOHANNESBURG	ORAL LIQUIDS, SEMI SOLIDS, ORAL SOLIDS (TABLETS, CAPSULES)	FDA/GMP/010/06/17	**April-22**
81	SOUTH AFRICA	**FRESENIUS KABI MANUFACTURING**	6 GIBAUD ROAD KORTEN SOUTH AFRICA 6020	SMALL AND LARGE VOLUME PARENTERALS	FDA/GMP/012/06/17	**April-22**
82	INDIA	**MEDOPHARM PRIVATE LIMITED (UNIT I & II)**	NO.50 KAYARAMBEDU VILLAGE, GUDUVANCHERY-603 202, TAMIL NADU INDIA	ORAL SOLIDS-BETA LACTAMS (TABLETS, DRY POWDER FOR SUSP.)	FDA/GMP/001/08/17	**April-22**

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	CERTIFICATE NUMBER	VALID UNTIL
83	INDIA	**AUROLAB**	NO.1, SIVAGANGA MAIN ROAD, VEERAPANJAN, MADURAI 625020, TAMIL NADU, INDIA	STERILE OPHTHALMIC PRODUCTS	FDA/GMP/002/08/17	**April-22**
84	INDIA	**M/S ATOZ PHARMACEUTICAL PVT LIMITED**	NO.12, BALAJI NAGAR AMBATTUR, CHENNAI	ORAL SOLIDS (TABLETS, HARD GELATINE CAPSULES), CEPHALOSPORIN: (TABLETS, CAPSULES, DRY SYRUPS)	FDA/GMP/003/08/17	**April-22**
85	INDIA	**MYLAN LABORATORIES LIMITED, AHMEDABAD**	PLOT NO. 20 & 21, PHARMEZ, THE PHARMACEUTICAL SPECIAL ECONOMIC ZONE, SARKHEJ-BAVLA HIGHWAY, VIL:MATODA, TAL SANAND AHMEDABAD, 382110	ORAL SOLIDS (TABLETS AND CAPSULES), SMALL VOLUME PARENTERALS	FDA/GMP/004/08/17	**May-22**
86	INDIA	**BHARAT SERUMS AND VACCINES LIMITED (UNIT I & II)**	PLOT NO. K-27, ANAND NAGAR, ADDITIONAL M.I.D.C, AMBERNATH (EAST), 421 501, THANE, MAHARASHTRA, INDIA	ANTISERA, rDNA DERIVED MEDICINES, HORMONAL PRODUCTS	FDA/GMP/005/08/17	**May-22**
87	INDIA	**AJANTA PHARMA LIMITED**	PLOT NO. Z/103/A, DAHEJ SEZ, PART-II, BHARUCH, GUJARAT 392 130	ORAL SOLIDS (COATED AND UNCOATED TABLETS, CAPSULES), ORAL JELLY	FDA/GMP/006/08/17	**May-22**
88	INDIA	**PANACEA BIOTEC LIMITED (VACCINE FORMULATION FACILITY)**	MALPUR, TEHSIL-BADDI, DISTRICT SOLAN (H.P) - 173205, INDIA	VACCINES	FDA/GMP/007/08/17	**May-22**
89	INDIA	**THEON PHARMACEUTICALS LIMITED**	VILLAGE: SAINIMAJARA, TEHSIL: NALAGARH-174101 DIST:SOLAN, HIMACHAL PRADESH, INDIA	ORAL SOLIDS (TABLETS, CAPSULES), POWDER FOR INJECTION	FDA/GMP/008/08/17	**May-22**
90	INDIA	**ADORE PHARMACEUTICALS PVT LIMITED**	5/6 KHOKHANI INDUSTRIAL COMPLEX, NO.2, OPP. NEELKANTH ESTATE, NEAR SAI TEMPLE, VASAI [E], THANE – 401 208, INDIA	SMALL VOLUME PARENTERALS, OPTHALMIC PREPARATIONS (EYE, EAR, NASAL DROPS/SPRAYS)	FDA/GMP/009/08/17	**May-22**

SUSPENDED LICENSES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE		VALID UNTIL
NIL	NIL	NIL	NIL	NIL		NIL

CANCELLED / REVOKED LICENSES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE		VALID UNTIL
NIL	NIL	**NIL**	**NIL**	NIL		**NIL**

MANUFACTURING FACILITIES DEPARTMENT

LIST OF LOCAL PHARMACEUTICAL MANUFACTURING FACILITIES AS AT JULY 2022

VALID LICENCES						
NO.	REGION	COMPANY	LOCATION ADDRESS	DOSAGE FORM	LICENCE NUMBER	VALID UNTIL
1	AR	**Pro-Life Infusions Limited**	Yonso, Odumasi, Via Jamasi, Ashanti Region 0245460540, 0200139291	Large Volume Parenterals	PPM/GMP/032/10/21	**July-22**
2	AR	**Aspee Pharmaceuticals**	Plt 66, Blk F, Asamang-Ejisu 0244791052 0208121450 0264791052 aspee2013@gmail.com	Oral Tablets, Oral Liquids	PPM/GMP/033/11/21	**August-22**
3	GAR	**Sanbao (GH) Pharmaceuticals Limited**	Plot No.2, Garment Village Street, Tema Export Processing Zone 0244375505 0243511275 0244209978 info@sanbaopharma.com.gh	Large Volume Parenterals	PPM/GMP/034/11/21	**September-22**
4	GAR	**Unichem Liquid Industries**	Plot Number 48, Tema Industrial Estate, Spintex Road, Accra 0302222645 0302227722 0302238180 headoffice@unichemghana.com	Oral (Tablets, Capsules, Liquids)	PPM/GMP/001/01/22	**December-22**
5	GAR	**Pharmanova Limited**	No. 3, Okodan Street, Osu-Manhean, Accra-Ghana 0544340309 0302766589	Oral (Tablets, Capsules, Powders, Dry Powders for Suspension)	PPM/GMP/005/02/22	**January-23**

6	GAR	**Atlantic Lifesciences Limited**	Plot Number. 16/01, Larpleku, Tema-Aflao, Accra 0302 -766568/766581	Large Volume Parenterals , Small Volume Parenterals, Inhalational Anaesthetics, Immunoglobulin And Vaccine Fillings, Opthalmic Preparations, Hand Sanitizers	PPM/GMP/004/02/22	**January-23**
7	GAR	**Danadams Pharmaceuticals Limited**	67 Nungua Link, Spintex Road, Baatsona, Accra 0302811672 0302811673 info@danadamsgh.com	Oral (Tablets, Capsules, Powders)	PPM/GMP/014/03/22	**February-23**
8	GAR	**Dannex Ayrton Starwin PLC**	5 Dadeban Rd., Ring Road North, North Industrial Area, Accra. 0302232574/5 info@dannexgh.com	Oral (Tablets, Capsules, Powders, Liquids), Topical (liquids, Ointment, creams, jelly, paste), Veterinary Drugs	PPM/GMP/017/03/22	**February-23**
9	GAR	**Eskay Therapeutics Limited**	42, South Industrial Area, Accra-Ghana 0555133337 admin@eskaypharma.com	Oral (Tablets, Capsules)	PPM/GMP/013/03/22	**February-23**
10	GAR	**Geo-Medicore Limited**	Plot No. 312-315, Kuntunse, Accra 0244364713 kboison60@hotmail.com	Oral (Tablets, Capsules, Liquids, Powders)	PPM/GMP/002/01/22	**February-23**
11	GAR	**Kinapharma Limited**	B 920/10, Mausoleum Lane, Dadeban Rd., North Industrial Area, North Kaneshie, Accra 0302220390 0302239751 info@kinapharma.com	Oral(Tablets, Capsules, Powders, syrups/ suspensions, elixirs) Topical(Tinctures, Ointment)	PPM/GMP/016/03/22	**February-23**
12	GAR	**M &G Pharmaceuticals Limited**	D 44/1 Bannerman Road, Jamestown Accra. 0302666613 0302664758 0302666868 mgpharm@vodafone.com.gh	Oral (Tablets, Capsules, Liquids Powders), Beta-lactams (tablets)	PPM/GMP/003/02/22	**February-23**
13	GAR	**New Global Pharma Limited**	Plot No. 1 Light Industrial area, Odorkor, Tipper Junction-Accra 0209053603 0246370661	Oral (Tablets, Liquids, Capsules)	PPM/GMP/012/03/22	**February-23**

14	GAR	**Pam Pharmaceuticals Limited**	Plot No. 5 Sector 2 Block A, Nsawam, Akwapim South E/R 0244866658	Oral (Tablets, Capsules, Caplets & Powders)	PPM/GMP/023/04/22	**February-23**
15	GAR	**Perfect Pharmaceuticals Limited**	Plot No. 1, Motorway-East Industrial Estate, off Spintex Road(After Coca Cola)Okpoi Gonno, Accra 0302816004	Oral (Tablets capsules, powders & syrups)	PPM/GMP/015/03/22	**February-23**
16	AR	**Kash Chemist Limited**	Plot 25 Block XII, New Amakom, Near St. Paul Catholic Church, Kumasi, Ashanti Region 0244674843	Oral Liquids	PPM/GMP/009/03/22	**February-23**
17	AR	**Amponsah Effah Pharmaceuticals Ltd**	Plt. 2 Kobi Street, Fumesua, Kumasi 0244618855	Oral (Tablets, Liquid including solutions, suspensions, tinctures, elixirs)	PPM/GMP/010/03/22	**March-23**
18	GAR	**Ernest Chemist Limited**	Plt No. 16/17, Heavy Industrial Area, Tema 0302252592 0302257141 info@ernestchemists.com	Oral (Tablets, Capsules, Powders, Liquids), Liquids for External Use	PPM/GMP/024/04/22	**March-23**
19	GAR	**Golden Tower Limited**	H/No. 34 North Industrial Area Opposite Apra House, Off 2nd Palace Link. Accra-Ghana 0302231529 goldentower1981@gmail.com	Oral (Tablets, Capsules, Liquid)	PPM/GMP/021/03/22	**March-23**
20	GAR	**Kama Health Services**	Plot No. 8, Ring Road East. West Labadi, Light. Industrial Area 0302782705 0302782707 info@aspenghana.com	Oral (Liquids, Capsules, Tablets, Syrups, Suspensions) and Tinctures	PPM/GMP/025/04/22	**March-23**
21	GAR	**Letap Pharmaceuticals Limited**	Plt. No. 107, Graphic Rd., South Industrial Area 030225838	Oral(Tablets, Capsules, Syrups/Suspension, Dry Powders)	PPM/GMP/020/03/22	**March-23**
22	GAR	**Maridav Ghana Limited**	Plot No. 42/2, Heavy Industrial Area, Tema 0303938088	Oral Powders for Veterinary Use	PPM/GMP/018/03/22	**March-23**
23	AR	**Omer Investment Limited**	Plot 76 Blk F, Suame, Kumasi 0208196549	Oral Liquids	PPM/GMP/019/03/22	**March-23**
24	GAR	**Phyto-Riker Pharmaceuticals Limited**	Plot 329 Mile 7, off Accra-Nsawam Rd., Dome-Accra 0264471717	Oral (Tablets, Capsules, Powders, Liquids)	PPM/GMP/022/03/22	**March-23**
25	AR	**Propharm Chemist**	Plot 27, Block L, Appiadu-Kumasi 0244760653 0234956852	Oral Liquids	PPM/GMP/006/03/22	**March-23**
26	AR	**Salom Pharmacy**	Plot 7B Blk 1. Asokore Mampong Industrial Area, Kumasi 0209412898	Oral Tablets	PPM/GMP/008/03/22	**March-23**
27	AR	**Trade Winds Chemists**	Plt 9b Blk.1 Ayigya Indusrial Area, Kumasi 0322092016 info@tradewindschemist.com	Oral (Tablets, Capsules, Liquid including solutions, suspensions, tinctures, elixirs & Powders)	PPM/GMP/011/03/22	**March-23**
28	AR	**Poku Pharma Limited**	Plot 12 Tottoe Street,Fumesua-Kumasi, Ashanti Region 0322064220 0322064223	Oral Solids, Oral Liquids	PPM/GMP/007/03/22	**March-23**
29	GAR	**Entrance Industries & Research centre**	No. 16 Okpoi Gonno, Spintex Road, Accra. 0302 234375	Oral (Liquids, Syrups and Powder, Tablets, Capsules) Creams and Ointments, Suppositories Beta Lactam (Tablets, Liquids, Capsules)	PPM/GMP/028/06/22	**April-23**
30	GAR	**GR Industries Limited**	15/5 Valco Road, Industrial Area, Tema-Ghana 0303211656 sales@grghana.com	Oral (Tablets, Capsules, Liquids)	PPM/GMP/026/05/22	**April-23**

31	ER	Intravenous Infusions Ltd	Plot 4-7 Blk L, Effiduase-Koforidua 0342020141 0342020151 0342020440 info@iil.com.gh	Large Volume Parenterals, Small Volume Parenterals	PPM/GMP/029/06/22	April-23
32	GAR	OA&J Pharmaceuticals Limited	Plot No. IND/A/71/G/11 Tema, Accra 0540677629 oajpharma@gmail.com	Oral (Tablets, Liquids, Capsules)	PPM/GMP/027/06/22	June-23

EXPIRED LICENCES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE	LICENCE NUMBER	VALID UNTIL
1	AR	AS Tesco Investment Company Limited	Plot 4 Block S, Boadi Industrial Area, Kumasi, Ashanti Region	Oral Liquids	PPM/GMP/015/03/21	November-21
2	GAR	AS Pharmaceuticals Limited	Near Mambo Spot, Sowutuom, Accra 0208196904	Oral Tablets	PPM/GMP/009/02/21	February-22
3	WR	O'Nart Pharmacy Limited	Plot 69, 76 Clinic Street, Apowa, Takoradi, Western Region 0206926523	Extemporaneous Preparations	PPM/GMP/011/02/21	February-22
4	GAR	Kanbros Chemical Industries Limited	1 Mensahwood Road, East Legon, Accra 0277554081	Oral Liquids	PPM/GMP/006/02/21	March-22
5	GAR	Kafnam Company Limited	House No. 115 Israel Junction Rd close to Tantra Hills 0242560889 laudtk@yahoo.com	Oral Liquids	PPM/GMP/031/07/21	April-22

SUSPENDED LICENSES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE		VALID UNTIL
NIL	NIL	NIL	NIL	NIL		NIL

CANCELLED / REVOKED LICENSES

NO.	COUNTRY	COMPANY	FACILITY LOCATION	DOSAGE FORMS / PRODUCT TYPE		VALID UNTIL